Immunomodulatory substances

JP2023550276A5Inactive Publication Date: 2024-11-05QUEENS UNIV OF BELFAST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526189
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-29
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Some vaccines fail to stimulate the adaptive immune system sufficiently and may require large amounts of foreign microbial material, which can be harmful, necessitating the use of immunomodulators to enhance their effectiveness.

Method used

Polysaccharides with a specific structure, comprising alpha-(1-5)-linked arabinofuranose residues as a backbone and side chains, are used to modulate immune responses, including stimulating or attenuating T H1 and T H2 responses, and are derived from plants of the Malvales order, particularly Sida cordifolia.

Benefits of technology

The polysaccharides effectively stimulate or suppress immune responses, are non-toxic, and can be administered orally, enhancing immune function against infections and preventing allergic reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022090735000001
    Figure 2022090735000001
  • Figure 2022090735000002
    Figure 2022090735000002
  • Figure 2022090735000003
    Figure 2022090735000003
Patent Text Reader

Abstract

The present invention relates to polysaccharides that can be used to modulate immune responses.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to polysaccharides, methods for isolating the polysaccharides, compositions containing the polysaccharides, polysaccharides for use as pharmaceuticals, methods for treatment using the polysaccharides, and other specific medical uses of the polysaccharides. [Background technology]

[0002] The innate immune system acts as the first line of defense when microorganisms invade the body of an animal or human. The adaptive immune system is the second line of defense, activated when the innate immune system fails to eliminate the microorganisms. Unlike the innate immune system, the adaptive immune system exhibits specificity to the unique antigens present in the invading microorganisms and remembers these specific antigens even after the microorganisms have been removed from the body. These characteristics of the adaptive immune system allow for more rapid elimination of specific antigens (and associated microorganisms) during a second or third invasion of the body, which is the basis for the function of vaccines.

[0003] Vaccines generally contain antigens that stimulate the adaptive immune system. Therefore, when encountering live microorganisms with the same antigen, the adaptive immune system's memory B cells and memory T cells (which remember the antigen and are formed from naive T cells after the initial encounter) modulate a more specific and effective immune response to eliminate the antigen / microorganism more quickly.

[0004] Mature B cells (B lymphocytes) generally function by producing antibodies against extracellular microorganisms, while mature T lymphocytes generally help kill intracellular microorganisms. CD8+ T cells, also known as cytotoxic T cells, kill intracellular microorganisms by binding to infected cells and releasing cytotoxic substances. Helper T cells (T HCD4+ T cells, also known as TH1 cells, provide protection against intracellular microorganisms by producing cytokines that induce the activation of inflammatory responses (via macrophage activation) or cytokines that induce the activation of humoral responses (by B cell activation). Helper T cells that induce the activation of inflammatory responses are called TH1 cells, and helper T cells that induce the activation of humoral responses are called T H They are called two-celled organisms.

[0005] Unfortunately, some vaccines fail to stimulate a sufficient adaptive immune system to form an appropriate response to microorganisms. Alternatively or additionally, some vaccines require large amounts of exogenous microbial material to induce an immune response. However, too much microbial material in a vaccine can be harmful to the user. As a result of these and other issues, some vaccines are administered with immunomodulatory substances (e.g., adjuvants) to enhance their effectiveness. For adjuvants to be effective, they must stimulate the relevant adaptive immune response (e.g., T). H 1. Intermediate immune response or T H It must be able to enhance the (2) mediated immune response.

[0006] Therefore, there is a need for immunomodulatory substances that can be used to regulate adaptive immune responses. [Overview of the Initiative]

[0007] According to a first aspect of the present invention, a polysaccharide comprising an "n" repeating unit is provided, wherein each "n" repeating unit comprises an alpha-(1-5)-linked arabinofuranose residue as a backbone, a first side chain which is a single alpha-arabinofuranose residue (1-2) bound to the arabinofuranose residue of the backbone, and a second side chain which is a single alpha-arabinofuranose residue (1-3) bound to the same arabinofuranose residue of the backbone.

[0008] The inventors have found that extracts of various plants exhibit immunomodulatory properties (see Example 3). In Example 4, it was confirmed that novel polysaccharides are involved in the observed immunomodulatory activity. Therefore, advantageously, the polysaccharides according to the invention can be used for the regulation (i.e., stimulation and / or attenuation) of the immune response. As shown in the examples, the polysaccharides are particularly effective in inducing the T H 1-mediated immune response. However, considering that the T H 1 response and the T H 2 response have opposing effects, it will be understood that the polysaccharides of the invention can be used to attenuate or prevent the T H 2-mediated immune response. Therefore, the polysaccharides according to the invention can be used for the stimulation and / or enhancement of the immune response, as well as for the termination and / or attenuation of the immune response. The polysaccharides are also edible, non-toxic and effective after oral ingestion, and are advantageous in that they do not induce anaphylaxis. Therefore, they may be administered orally.

[0009] The polysaccharides according to the invention may have one or more of the following capabilities: · Induce or enhance the release of T H 1 cytokines (such as IFNγ, TNFα and / or IL-2); · Induce or enhance the proliferation of lymphocytes (such as T cells and / or B cells); · Induce or enhance the production of IgM, IgA and / or IgG antibodies; · Activate macrophages (such as activation of iNOS / release of NO and / or release of O2-) or enhance their activation; · Induce or enhance the phagocytic action by macrophages; · Have a prebiotic effect (act as a substrate for beneficial bacteria or fungi colonizing the intestine, thereby stimulating their growth and / or activity); · Induce or enhance the release of IL-6 and / or TNFα, particularly in macrophages; · Induce or enhance the release of IL-6 and / or IL-12, particularly in microglia; • Induce or enhance the release of IL-9, IL-6, and / or IL-71A by immune cells; • Induces or enhances IL-8 production in immune cells; • Inhibits or suppresses the production of MIG (gamma-induced monokine) in immune cells.

[0010] Therefore, the polysaccharides according to the present invention may be able to treat, prevent, or improve infections caused by foreign substances or microorganisms such as bacteria, fungi, and / or viruses.

[0011] The polysaccharide according to the present invention may have one or more of the following abilities. T H 2. To attenuate or prevent the release of cytokines (e.g., IL-4, IL-5, IL-9, IL-10, IL-13, and / or IL-25); • Prevent or attenuate B cell class switching to IgE; • Prevent or reduce the release of IgE antibodies; • Prevent or reduce the degranulation of mast cells; • Prevents or inhibits basophil degranulation; • To prevent or inhibit eosinophilia; • Prevents or inhibits the activation of dendritic cells.

[0012] The polysaccharides of the present invention can be isolated from Malvales plants. The polysaccharides of the present invention can be isolated from plants of the Malvales order. The Malvales order includes the Bixaceae family, Cistaceae family, Cytinaceae family, Dipterocarpaceae family, Muntingiaceae family, Neuradaceae family, Sarcloaenaceae family, Sphaerosepalaceae family, Thymelaeceae family, and Malvaceae family. Preferably, the plant is a member of the Malvaceae family. The Malvaceae family includes the subfamilies Bombacoideae, Brownlowioideae, Bytnnerioideae, Byttnerioideae, Dombeyoideae, Grewioideae, Helicteroideae, Malvoideae, Sterculioideae, and Tiliodeae. Preferably, the plant is Malvoideae. Malvoideae includes the tribes Malveae, Gossypieae, Hibisceae, and Kydieae. Preferably, the plants are derived from the tribe Malveae.The plants may be derived from the genera Malva, Malvastrum, Sidalcea, Abutilon, Althea, Sphaeralcea, or Lavatera. Most preferably, the plants of the fern family are Sida cordifolia (also known as ilima, flannel weed, bala, country mallow, or heart-leaf sida). Most preferably, the plants of the genus Malva are Malva sylvestris. Most preferably, the plant of the genus Malvastrum is Malvastrum lateritium. Most preferably, the plant of the genus Sidalcea is Sidalcea malviflora. Most preferably, the plant of the genus Abutilon is Abutilon theophrasti. Most preferably, the plant of the genus Althea is Althea officinalis. Most preferably, the plant of the genus Sphaeralcea is Sphaeralcea coccinea. Most preferably, the plant of the genus Lavatera is Lavatera arborea. Most preferably, the plant is the fern Sida cordifolia.

[0013] Thus, polysaccharides can be isolated from the genera *Fern* (e.g., *Sida cordifolia*), *Malva* (e.g., *Malva sylvestris*), *Malvastrum* (e.g., *Malvastrum lateritium*), *Sidalcea* (e.g., *Sidalcea malviflora*), *Althea* (e.g., *Althea officinalis*), *Sphaeralcea* (e.g., *Sphaeralcea coccinea*), or *Lavatera* (e.g., *Lavatera arborea*).

[0014] Preferably, the polysaccharide is a polysaccharide isolated from Sida cordifolia. The polysaccharide can be isolated from a part of the plant, e.g., the leaves, flowers, stems and / or roots of the plant. Preferably, the polysaccharide is isolated from the roots of plants of the Malvales order. Thus, the polysaccharide can be isolated from the roots of ferns spp. (e.g., Sida cordifolia), or Malva spp. (e.g., Malva sylvestris), or Malvastrum spp. (e.g., Malvastrum lateritium), or Sidalcea spp. (e.g., Sidalcea malviflora). Most preferably, the polysaccharide is isolated from the roots of the fern Sida cordifolia.

[0015] The polysaccharide according to the present invention may be a homopolysaccharide or a heteropolysaccharide. The polysaccharide may be an arabinane polysaccharide. The polysaccharide may be an arabinane homopolysaccharide. The residues of the homopolysaccharide may be L-arabinofuranose residues or D-arabinofuranose residues. Preferably, the residues are L-arabinofuranose residues.

[0016] Each repeating unit of the polysaccharide skeleton according to the first embodiment further comprises three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten additional residues at the terminal residues of the skeleton. Preferably, the additional residues of the skeleton are alpha-(1-5)-linked arabinofuranose residues. Most preferably, the additional residues of the skeleton are alpha-L-(1-5)-linked arabinofuranose residues. One or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or nine or more additional alpha-(1-5)-linked arabinofuranose residues may or may not contain any side chains. One or more additional alpha-(1-5)-linked arabinofuranose residues may contain a single alpha-(1-2)-linked arabinofuranose residue as a side chain. One or more additional alpha-(1-5)-linked arabinofuranose residues may include a single alpha-(1-3)-linked arabinofuranose residue as a side chain. One, two, or three additional alpha-(1-5)-linked arabinofuranose residues may include a single alpha-(1-2) that binds to an arabinofuranose residue as a side chain and a single alpha-arabinofuranose residue (1-3) that binds to the same additional arabinofuranose residue in the backbone as a side chain.

[0017] Each repeating unit may be independently branched or unbranched. Thus, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the repeating units may be branched. Thus, repeating units of less than approximately 100%, less than approximately 90%, less than approximately 95%, less than approximately 90%, less than approximately 85%, less than approximately 80%, less than approximately 75%, less than approximately 70%, less than approximately 65%, less than approximately 60%, less than approximately 55%, less than approximately 50%, less than approximately 45%, less than approximately 40%, less than approximately 35%, less than approximately 30%, less than approximately 25%, less than approximately 20%, less than approximately 15%, less than approximately 10%, or less than approximately 5% may be branched.

[0018] Each repeating unit may be directly or indirectly linked to one another. Preferably, each repeating unit is directly linked to one another via glycosidic bonds, such as alpha-(1-5) glycosidic bonds or alpha-L-(1-5) glycosidic bonds.

[0019] The first and second side chains of the polysaccharide according to the present invention can be bound to the same arabinofuranose residue in the backbone.

[0020] In one embodiment, the repeating unit is defined herein as formula (I) (sometimes referred to herein as block "A"): [ka] It includes or consists of.

[0021] The polysaccharide repeating unit according to the present invention includes or may consist of blocks referred to herein as blocks "A", "E", and "F". Thus, the polysaccharide repeating unit may further include block E and / or block F.

[0022] The iteration unit is given by the following equation (II): [ka] This may further include block E, indicated by [the symbol].

[0023] The iteration unit is given by the following equation (III): [ka] This may further include block F, which is shown as follows.

[0024] Each block (i.e., block A, block E, and block F) contains a skeleton. Each block can be connected by an alpha-(1-5)-glycosidic bond, specifically by the skeleton of each block. Thus, the repeating unit may contain formula (I) to which formula (II) is connected by an alpha-(1-5)-glycosidic bond. The repeating unit may contain formula (I) to which formula (III) is connected by an alpha-(1-5)-glycosidic bond. The repeating unit may contain formula (II) to which formula (III) is connected by an alpha-(1-5)-glycosidic bond.

[0025] Preferably, block F (if present in the iteration unit) is the least abundant of A, E, and F. Preferably, block A is the most abundant of A, E, and F. Block F (if present in the iteration unit) may be about 2, 3, 4, 5, 6, 7 or less in abundance than block A. Block F (if present) may be about 1 to 2 times less in abundance than block A. Preferably, for every occurrence of F, there are about 4 to 6 occurrences of A, and for every occurrence of F, there are about 1 to 2 occurrences of E. Thus, the A:E:F ratio in the iteration unit may be about 2 to 8:1 to 3:1 or about 3 to 7:1 to 2:1 or about 4 to 6:1 to 2:1. Most preferably, the A:E:F ratio is about 4 to 6:1 to 2:1. The A:F ratio in the iteration unit may be about 2 to 8:1 or about 3 to 7:1 or about 4 to 6:1. Most preferably, the A:F ratio is about 4 to 6:1. The A:E ratio in the repeating unit may be about 2 to 8:1, or about 2 to 7:1, or about 2 to 6:1. Most preferably, the A:F ratio is about 2 to 6:1.

[0026] The iteration unit is defined in this specification as follows: Formula (IV): [ka] [In each formula (IV), the asterisk corresponds to arabinofuranose, preferably L-arabinofuranose, more preferably alpha-arabinofuranose, and most preferably alpha-L-arabinofuranose.] It may include.

[0027] The repeating unit of the polysaccharide according to the present invention is represented by one of the combinations shown in Table 1 below: [Table 1]

[0028] Each cell in Table 1 above represents an embodiment of the polysaccharide repeating unit according to the present invention. Thus, the polysaccharide repeating unit of the present invention may be represented by any one of the 48 examples shown in Table 1. The polysaccharide of the present invention may contain "n" repeating units, for example, formula (I) or formula (IV) or "n" repeating units of any of the 48 examples shown in Table 1. "n" may be 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, or 40 or more, 50 or more, 100 or more, 200 or more, 300 or more, 500 or more, or 1000 or more. "n" can be approximately 5 to 1000, approximately 10 to 500, or approximately 15 to 250, or approximately 15 to 230, or approximately 15 to 220. Preferably, "n" is approximately 15 to 220 or approximately 15 to 230.

[0029] The polysaccharides according to the present invention can be used to modulate, preferably, stimulate, the immune response of a target. The inventors have found that as the molecular weight increases, the regulatory effect on the immune response per unit weight of the polysaccharide also increases. The average molecular weight of the polysaccharide according to the present invention, or the repeating unit of the polysaccharide according to the present invention, may be at least about 3 kDa, at least about 5 kDa, at least about 10 kDa, at least about 15 kDa, at least about 20 kDa, at least about 25 kDa, at least about 30 kDa, at least about 35 kDa, at least about 40 kDa, at least about 50 kDa, at least about 60 kDa, at least about 65 kDa, at least about 70 kDa, at least about 75 kDa, at least about 80 kDa, at least about 85 kDa, at least about 90 kDa, at least about 95 kDa, at least about 100 kDa, at least about 105 kDa, at least about 110 kDa, or at least about 115 kDa.

[0030] The polysaccharides according to the present invention range from approximately 3kDa to approximately 200kDa, 4kDa to approximately 180kDa, 5kDa to approximately 160kDa, 6kDa to approximately 140kDa, approximately 7kDa to approximately 120kDa, approximately 8kDa to approximately 120kDa, approximately 9kDa to approximately 120kDa, approximately 10kDa to approximately 120kDa, approximately 20kDa to approximately 120kDa, and approximately 30kDa to approximately 120kDa. The average molecular weight may be approximately 120 kDa, approximately 40 kDa to approximately 120 kDa, approximately 50 kDa to approximately 120 kDa, approximately 60 kDa to approximately 120 kDa, approximately 70 kDa to approximately 120 kDa, approximately 80 kDa to approximately 120 kDa, approximately 90 kDa to approximately 120 kDa, approximately 100 kDa to approximately 120 kDa, or approximately 110 kDa to approximately 120 kDa. Preferably, the polysaccharide has a molecular weight of 0 kD to 120 kDa.

[0031] The polysaccharides of the present invention are administered via several different routes, including, for example, oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), percutaneous, intracisional, intraperitoneal, vaginal, and non-enteral (subcutaneous, intramuscular, intrathecal, intravenous, and intradermal) routes. Preferably, the polysaccharides are administered orally.

[0032] The polysaccharide according to the present invention is non-toxic, especially in humans. The polysaccharide according to the present invention is non-toxic at doses up to 100 μg / ml. The polysaccharide according to the present invention is non-toxic, especially in humans, at doses up to 100 μg / ml.

[0033] The polysaccharide according to the present invention may be rhamnogalacturonan, for example, rhamnogalacturonan-I of rhamnogalacturonan-II, or it may be any other.

[0034] In another embodiment, a method for isolating the polysaccharide according to the present invention from the Malvales plant, i. Homogenizing and dehydrating Malvales plants to form dehydrated Malvales plant particles or powder; and ii. Isolating polysaccharides from Malvales plants by extracting polysaccharides from dehydrated Malvales plant particles and / or powder. A method including this is provided.

[0035] The method according to the present invention may involve isolating polysaccharides from a member of the Malvales order or a part of that plant (such as a root). Therefore, the Malvales plant or a part of that plant may include plants of the Bixaceae family, Cistaceae family, Cytinaceae family, Dipterocarpaceae family, Muntingiaceae family, Neuradaceae family, Sarcloaenaceae family, Sphaerosepalaceae family, Thymelaeceae family, or Malvaceae family. Preferably, the plant is a member of the Malvaceae family. Therefore, members or parts of the Malvales plants may be subfamilies of the Malvaceae family. The Malvaceae subfamily includes Bombacoideae, Brownlowioideae, Bytnnerioideae, Byttnerioideae, Dombeyoideae, Grewioideae, Helicteroideae, Malvoideae, Sterculioideae, and Tiliodeae. Preferably, the plant is Malvoideae. Malvoideae plants may belong to the tribes Malveae, Gossypieae, Hibisceae, or Kydieae. Preferably, the plants belong to the tribe Malveae.The plants may belong to the genera Malva, Malvastrum, Sidalcea, Abutilon, Althea, Sphaeralcea, or Lavatera. Most preferably, the plant of the genus Malva is Sida cordifolia (also known as ilima, flannel weed, bala, country mallow, or heart-leaf sida). Most preferably, the plant of the genus Malva is Malva sylvestris. Most preferably, the plant of the genus Malvastrum is Malvastrum lateritium. Most preferably, the plant of the genus Sidalcea is Sidalcea malviflora. Most preferably, the plant of the genus Abutilon is Abutilon theophrasti. Most preferably, the plant of the genus Althea is Althea officinalis. Most preferably, the plant of the genus Sphaeralcea is Sphaeralcea coccinea. Most preferably, the plant of the genus Lavatera is Lavatera arborea. Most preferably, the plant is the fern Sida cordifolia.

[0036] Polysaccharides can be isolated from plants of the genera *Fern* (e.g., *Sida cordifolia*), *Malva* (e.g., *Malva sylvestris*), *Malvastrum* (e.g., *Malvastrum lateritium*), *Sidalcea* (e.g., *Sidalcea malviflora*), *Althea* (e.g., *Althea officinalis*), *Sphaeralcea* (e.g., *Sphaeralcea coccinea*), or *Lavatera* (e.g., *Lavatera arborea*). Preferably, the polysaccharide is a Sida cordifolia polysaccharide. The polysaccharide can be isolated from parts of Malvales plants, e.g., leaves, flowers, stems and / or roots of the plant. Preferably, the polysaccharide is isolated from the roots of Malvales plants. The polysaccharide can be isolated from the roots of ferns spp. (e.g., Sida cordifolia), or Malva spp. (e.g., Malva sylvestris), or Malvastrum spp. (e.g., Malvastrum lateritium), or Sidalcea spp. (e.g., Sidalcea malviflora). Most preferably, the polysaccharide is isolated from the roots of the fern Sida cordifolia.

[0037] The process of homogenizing and dehydrating Malvales plants may include dehydrating the plants before homogenizing the plant material, or dehydrating the plants after homogenization. Homogenizing Malvales plants involves increasing the surface area of ​​the plants and / or decreasing their size so that they form particles or powder. Dehydration involves removing water from Malvales plants.

[0038] Homogenizing Malvales plants may involve grinding and / or finely chopping the plants to produce particles and / or powder. Homogenizing plants may involve using an analytical mill. The particles or powder may be large enough to pass through a sieve with a size equal to or less than approximately 0.8 mm.

[0039] The dehydration process for Malvales plants may include removing moisture from the plant material by freeze-drying or heating. Preferably, the dehydration includes freeze-drying.

[0040] The process for extracting polysaccharides from Malvales plants may include one or more selected from the group consisting of water-alcohol precipitation, dilute alkaline leaching, enzymatic treatment, microwave extraction, ultrasonic extraction, ultrasonic-mediated enzymatic extraction, vacuum extraction, and pulsed field extraction. Preferably, the process for extracting polysaccharides includes water-alcohol precipitation.

[0041] The process of extracting polysaccharides from dehydrated Malvales plant particles may include one or more alcohol extraction steps (e.g., ethanol extraction steps) for separating the dehydrated Malvales plant particles or powder into an alcohol phase and a particle phase, or for separating the aqueous phase into an alcohol phase and a precipitate. The process for extracting polysaccharides from dehydrated Malvales plant particles may include one or more aqueous extraction steps, such as separating the dehydrated Malvales plant particles into an aqueous phase and a precipitate, or separating the alcohol phase into an aqueous phase and a precipitate.

[0042] The process of extracting polysaccharides from dehydrated Malvales plant particles may include one or more alcohol extraction steps and / or one or more aqueous extraction steps.

[0043] The aqueous extraction step may be carried out using an aqueous solution such as water, saline solution, or other salt-containing solution (e.g., phosphate-buffered saline solution). The alcohol extraction step may be carried out using ethanol. Preferably, there are two alcohol extraction steps, most preferably a first alcohol extraction step (e.g., an ethanol extraction step), followed by one or more aqueous extraction steps, and then a second (final) alcohol extraction step (e.g., an ethanol extraction step).

[0044] The (first) alcohol extraction step may include separating the dehydrated Malvales plant particles or powder into an alcohol phase and a particle phase. Preferably, the alcohol extraction step is carried out with simultaneous stirring for at least about 4 hours, at least about 8 hours, or at least about 12 hours, optionally throughout the entire alcohol extraction step. The alcohol phase and precipitate can be separated by centrifugation. Centrifugation may be carried out at about 6000 rpm to about 7000 rpm, preferably about 6500 rpm. Centrifugation may be carried out at about 0.1 to less than about 10°C, about 1°C to 9°C, about 2°C to 8°C, about 2°C to 7°C, about 3°C ​​to 6°C, or about 3°C ​​to 6°C. Preferably, centrifugation is carried out at about 4°C. Centrifugation may be carried out for about 10 minutes or more, about 20 minutes or more, about 30 minutes or more, or 1 hour or more. Preferably, centrifugation is carried out for about 30 minutes or more. Centrifugation may be performed at approximately 6000 rpm to approximately 7000 rpm or approximately 6500 rpm at approximately 4°C for approximately 10 minutes or more, approximately 20 minutes or more, or approximately 30 minutes or more. The alcohol phase may be discarded. The polysaccharide-containing particulate phase according to the present invention may be retained. The (first) alcohol extraction step may be performed at room temperature using 95% alcohol (e.g., ethanol).

[0045] One or more aqueous extraction steps may be one or more, two or more, three or more, four or more, five or more, or six or more aqueous extraction steps. One or more aqueous extraction steps may include separating the precipitate from the first alcohol extraction step or aqueous extraction step into an aqueous phase and a precipitate. One or more aqueous extraction steps may be carried out using a boiling aqueous solution, preferably an aqueous solution maintained at a temperature of about 100°C (throughout the entire extraction process). The aqueous extraction steps may be carried out using a boiling aqueous solution such as water for about 30 minutes or more, about 1 hour or more, or about 2 hours or more. The aqueous extraction steps may include stirring throughout the entire aqueous extraction process. The aqueous phase and precipitate may be separated by centrifugation. Centrifugation may be carried out at about 6000 rpm to about 7000 rpm, preferably about 6500 rpm. Centrifugation may be carried out at approximately 0.1 to less than approximately 10°C, approximately 1°C to 9°C, approximately 2°C to 8°C, approximately 2°C to 7°C, approximately 3°C to 6°C, or approximately 3°C to 6°C. Preferably, centrifugation is carried out at approximately 4°C. Centrifugation may be carried out for approximately 10 minutes or more, approximately 20 minutes or more, approximately 30 minutes or more, or 1 hour or more. Preferably, centrifugation is carried out for approximately 30 minutes or more. Centrifugation may be carried out at approximately 6000 rpm to approximately 7000 rpm or approximately 6500 rpm, at approximately 4°C, for approximately 10 minutes or more, approximately 20 minutes or more, or 30 minutes or more. The separated aqueous phases from one or more aqueous extraction steps containing the polysaccharides according to the present invention may be stored together and pooled. The precipitates from the aqueous extraction steps may be used in further aqueous extraction steps to isolate further polysaccharides according to the present invention.

[0046] The aqueous phases from one or more combined aqueous extraction steps are treated with one or more enzymes at room temperature (or approximately 37°C) to digest unwanted carbohydrates and proteins, and optionally subsequently dialyzed. The enzymes may be selected from the group consisting of alpha-amylase, pullulanase, and protease K. Dialysis may be performed using water. Dialysis may have a pocket cutoff of approximately 12–14 kDa.

[0047] A second / final alcohol extraction step may be performed on the aqueous phase of one or more aqueous extraction steps that have been pooled together so that an alcohol phase and precipitate can be formed. Preferably, the second / final alcohol extraction step is performed on the aqueous phase of one or more aqueous extraction steps that have been pooled together, enzymatically treated, and dialyzed. The (second / final) alcohol extraction step may be performed using 80% alcohol (e.g., 80% ethanol) at room temperature (e.g., about 18–22°C). Preferably, the alcohol extraction step is performed with stirring optionally throughout the entire alcohol extraction step for at least about 4 hours, at least about 8 hours, or at least about 12 hours. The alcohol phase and precipitate can be separated by centrifugation. Centrifugation may be performed at about 6000 rpm to about 7000 rpm, preferably about 6500 rpm. Centrifugation may be performed at about 0.1–less than about 10°C, about 1°C–9°C, about 2°C–8°C, about 2°C–7°C, about 3°C–6°C, or about 3°C–6°C. Preferably, centrifugation is performed at about 4°C. Centrifugation may be performed for about 10 minutes or more, about 20 minutes or more, about 30 minutes or more, or 1 hour or more. Preferably, centrifugation is performed for about 30 minutes or more. Centrifugation is performed at about 6000 rpm to about 7000 rpm or about 6500 rpm at about 4°C for about 10 minutes or more, about 20 minutes or more, or about 30 minutes or more. The alcohol phase may be discarded. The polysaccharide-containing particulate phase according to the present invention may be used using chromatographic techniques known in the art or may be further concentrated. Chromatographic techniques known in the art include ion exchange chromatography, size exclusion chromatography, reversed-phase chromatography, high-performance liquid chromatography, and flash chromatography.

[0048] The method according to the present invention may include a final (iii) purification step. The purification step may include purifying the polysaccharide isolated from the Malvales plant using chromatography, crystallization, or distillation techniques.

[0049] In another embodiment, an isolated polysaccharide produced by the method according to the present invention is provided.

[0050] The polysaccharides according to the present invention can be used as cell culture additives. Accordingly, according to another embodiment, a culture medium is provided that contains an isolated polysaccharide according to the present invention or an isolated polysaccharide produced by a method according to the present invention.

[0051] The culture medium may further contain cells, biological tissues, biological organs, biological systems, or organisms.

[0052] The culture medium may be cloning medium or hybridoma feeder supplement (intended to improve cell cloning efficiency or hybridoma growth and viability).

[0053] The polysaccharides according to the present invention may be used as adjuncts to or in combination with known therapies for treating, improving, or preventing helper T cell-mediated diseases, such as vaccines, pharmaceutical compositions, or edible compositions (e.g., prebiotics). For example, the polysaccharides according to the present invention may be used in combination with known agents for treating various allergic disorders (e.g., hay fever), inflammatory disorders (e.g., asthma), and / or autoimmune disorders (e.g., rheumatoid arthritis), such as glucocorticoids, corticosteroids, methotrexate, disease-modifying antirheumatic drugs (DMARDs), Janus kinase (JAK) inhibitors, or cytokine-interacting biologics (e.g., etanercept).

[0054] Accordingly, according to another aspect of the present invention, a composition is provided comprising a polysaccharide according to the present invention or an isolated polysaccharide produced by a method according to the present invention, which optionally is a pharmaceutical composition and a pharmaceutically acceptable carrier, or an edible composition (e.g., a prebiotic).

[0055] According to another aspect of the present invention, an immunological adjuvant comprising a polysaccharide according to the present invention is provided.

[0056] According to another aspect of the present invention, a vaccine comprising an immunological adjuvant according to the present invention is provided.

[0057] In another embodiment, the present invention provides polysaccharides, compositions, isolated polysaccharides produced by methods according to the present invention, immunological adjuvants, or vaccines for use in pharmaceuticals.

[0058] In another embodiment, an immunological adjuvant or vaccine according to the present invention is provided for use in the vaccination of a target.

[0059] Immunological adjuvants or vaccines stimulate helper T cells (T H ) May be used for vaccination of subjects with interventional diseases or medical conditions. Helper T cells (T H ) Interventional diseases or conditions are T H 1. Interventional disease or condition, or T H 2. It may be an intermediary disease or medical condition.

[0060] In another embodiment, the present invention provides polysaccharides, isolated polysaccharides produced by a method according to the present invention, compositions according to the present invention, immunological adjuvants according to the present invention, or vaccines according to the present invention for use in treating, improving or preventing a disease or condition of interest.

[0061] In another aspect, the target helper T cell (T H )Polysaccharides, isolated polysaccharides produced by the method according to the present invention, immunoadjuvants according to the present invention or vaccines according to the present invention, or plants of the order Malvales or parts thereof, are provided for use in the treatment, improvement or prevention of intermittent diseases or conditions.

[0062] In another embodiment, a method for vaccinating a subject is provided, which includes administering an adjuvant or a vaccine according to the present invention to the subject.

[0063] In another aspect, helper T cells (T) in the subject H ) A method is provided for treating, improving or preventing an interventional disease or condition, comprising administering to a subject (i) a polysaccharide according to the present invention, (ii) an isolated polysaccharide produced by a method according to the present invention, (iii) a composition according to the present invention, (iv) an adjuvant according to the present invention, (v) a vaccine according to the present invention, or (vi) a plant of the order Malvales or a part thereof.

[0064] Advantageously, the adjuvant or vaccine according to the present invention enhances the immunomodulatory activity of the adjuvant-receiving target, H 1. The intermediated immune response is inactive, or T H This can lead to stimulation of the immune system for treating conditions in which the 2-mediated response is overactive.

[0065] The plant may be a plant of the order Malvales, as referred to herein, or a part of such a plant.

[0066] Therefore, helper T cells (T H ) Interventional diseases or conditions are T H 1. Interventional disease or condition, or T H 2. It may be an intermediary disease or medical condition.

[0067] T H 1. The intervening response is ineffective or inactive. H1. Interventional diseases or conditions include: rheumatoid arthritis (RA); psoriatic arthritis; psoriasis; inflammatory bowel syndrome (IBD); Crohn's disease; ulcerative colitis; multiple sclerosis (MS); influenza (including generalized influenza); respiratory disorders, such as those caused by viruses, including polynuclear respiratory virus (RSV); cystic fibrosis (CF); herpes (including genital herpes); sepsis and septic shock; bacterial pneumonia; bacterial meningitis; dengue hemorrhagic fever; endometriosis; prostatitis; uveitis; and uterine maturation. Ripening; Alopecia areata; Ankylosing spondylitis; Celiac disease; Dermatomyositis; Type 1 diabetes; Goodpasture syndrome; Graves' disease; Guillain-Barré syndrome; Juvenile idiopathic arthritis; Hashimoto's thyroiditis; Idiopathic thrombocytopenic purpura; Lupus erythematosus; Mixed connective tissue disease; Myasthenia gravis; Narcolepsy; Osteoarthritis; Pemphigus vulgaris; Pernicious anemia; Polymyositis; Primary biliary cirrhosis; Relapsing polychondritis; Sjögren's syndrome; Temporal arteritis; Vascularitis; Wegener's granulumatosis; Age-related macular degeneration; Infectious diseases (e.g., Mycobacterium tuberculosis (Mt) infection, Human immunodeficiency virus (HIV) infection, or Coronavirus infection)); Autoimmune disorders (e.g., Arthritis, Multiple sclerosis, or Type 1 diabetes); Cancer; Post-cancer surgery It may be one or more selected from the group including / consisting of surgery or cancer treatment and post-immunization. Preferably, T H 1. The underlying disease or condition is one or more of the following: cystic fibrosis (CF), type 1 diabetes mellitus, age-related macular degeneration, or infectious disease (e.g., Mycobacterium tubercurocystis (Mt) infection, human immunodeficiency virus (HIV) infection, or coronavirus infection). H 1. The underlying disease or condition may be cystic fibrosis (CF). H 1. The intervening disease or condition may be type 1 diabetes. H 1. The underlying disease or condition may be age-related macular degeneration. H 1. The underlying disease or condition may be an infectious disease. H1. The intervening disease or condition may be Mycobacterium tuberculosis (Mt) infection. H 1. The underlying disease or condition may be human immunodeficiency virus (HIV) infection. H 1. The underlying disease or condition may be a coronavirus infection.

[0068] T H T is a T-mediated response that is overactive. H 2. The intervening disease or condition may be one or more selected from the group including / consisting of type 1 hypersensitivity disorders (including allergies (e.g., rhinitis, allergic dermatitis, urticaria), asthma, eczema, hay fever, urticarial disease, chronic graft-versus-host disease, progressive systemic sclerosis, systemic lupus erythematosus); chronic lung disease; scleroderma; anaphylaxis; atrophy (e.g., muscle); and graft rejection. Preferably, T H 2. The intervening disease or condition is one or more of the following: allergies (e.g., rhinitis, allergic dermatitis, urticaria), asthma, eczema, and hay fever. H 2. The intervening disease or condition may be an allergy. H 2. The underlying disease or condition may be rhinitis. H 2. The underlying disease or condition may be allergic dermatitis. H 2. The underlying disease or condition may be urticaria. H 2. The underlying disease or condition may be asthma. H 2. The underlying disease or condition may be eczema. H 2. The underlying disease or condition may be hay fever (seasonal and / or perennial allergic rhinitis).

[0069] Therefore, in one embodiment, the subject may be selected from the group including / consisting of cystic fibrosis (CF), type 1 diabetes, age-related macular degeneration, and infectious diseases (e.g., Mycobacterium tubercurosis (Mt) infection, human immunodeficiency virus (HIV) infection, or coronavirus infection). HThere are polysaccharides according to the present invention, or isolated polysaccharides produced by the method according to the present invention, for use in the treatment, prevention, or improvement of 1-mediated diseases / conditions.

[0070] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method according to the present invention for use in the treatment, prevention, or improvement of cystic fibrosis (CF).

[0071] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of type 1 diabetes.

[0072] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of age-related macular degeneration.

[0073] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of infectious diseases (e.g., Mycobacterium tubercurosis (Mt) infection, human immunodeficiency virus (HIV) infection, or coronavirus infection).

[0074] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of Mycobacterium tuberculosis (Mt) infection.

[0075] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in treating, preventing, or improving human immunodeficiency virus (HIV) infection.

[0076] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in treating, preventing, or improving coronavirus infection.

[0077] In another embodiment, T is selected from the group including / consisting of allergies (e.g., rhinitis, allergic dermatitis, urticaria), asthma, eczema, and hay fever. H There are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of 2-mediated diseases / conditions.

[0078] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in treating, preventing or improving allergies.

[0079] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of rhinitis.

[0080] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of allergic dermatitis.

[0081] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of urticaria.

[0082] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of asthma.

[0083] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of eczema.

[0084] In another embodiment, there are polysaccharides according to the present invention or isolated polysaccharides produced by the method of the present invention for use in the treatment, prevention, or improvement of hay fever.

[0085] The polysaccharides, compositions, adjuvants, vaccines, and plants according to the present invention may be administered orally, by aerosol inhalation (e.g., nasal inhalation or oral inhalation), sublingually, topically, percutaneously, or non-enterally (subcutaneously, intramuscularly, or intravenously).

[0086] The polysaccharides or compositions according to the present invention may be administered orally. The polysaccharides or compositions according to the present invention may be administered by aerosol inhalation (e.g., nasal inhalation or oral inhalation). The polysaccharides or compositions according to the present invention may be administered sublingually. The polysaccharides or compositions according to the present invention may be administered topically. The polysaccharides or compositions according to the present invention may be administered transdermally. The polysaccharides or compositions according to the present invention may be administered non-enterally (subcutaneously, intramuscularly, or intravenously). Preferably, the polysaccharides or compositions according to the present invention are administered orally.

[0087] A treatment method according to the present invention may include administering a therapeutically effective amount of the polysaccharide, composition, adjuvant, or vaccine according to the present invention.

[0088] In another embodiment, a method for culturing cells, biological tissues, biological organs, biological systems, or organisms, The process of placing cells, biological tissues, biological organs, biological systems, or organisms in a culture medium, A method is provided comprising placing (i) a polysaccharide according to the present invention, (ii) an isolated polysaccharide produced by a method according to the present invention, (iii) a composition according to the present invention, (iv) an adjuvant according to the present invention, (v) a vaccine according to the present invention, or (vi) a plant of the order Malvales or a part thereof in a culture medium.

[0089] In another embodiment, T H 1. A method for inducing or enhancing an mediated immune response, T H A method is provided comprising administering or contacting a polysaccharide according to the present invention to an organism, a biological system, a biological tissue, a biological organ, or a cell in order to induce or enhance an mediated immune response.

[0090] T H 1. Intermediated immune response is T H This may include / may include one or more of the group comprising: 1. Production of cytokines (e.g., IFNγ, TNFα, and / or IL-2); induction of lymphocyte proliferation (e.g., T cell and / or B cell proliferation); production of IgM, IgA, and / or IgG antibodies; activation of macrophages (e.g., activation of iNOS / release of NO, release of O2-); and induction of phagocytosis by macrophages.

[0091] In another embodiment, T H 2. A method for preventing or attenuating an intermediated immune response, T H A method is provided comprising administering or contacting a polysaccharide according to the present invention to an organism, biological system, biological tissue, biological organ, or cell in order to prevent or attenuate an mediated immune response.

[0092] T H 2. Intermediated immune response is T H Production of 2 cytokines (e.g., IL-4, IL-5, IL-9, IL-10, IL-13, and IL-25); induction of B cell class switching to IgE, production of IgE antibodies; mast cell degranulation; basophil degranulation; eosinophil recruitment; and activation of dendritic cells, including / may include one or more of the group consisting of these.

[0093] The method according to the present invention may be an in vivo method, an ex vivo method, or an in vitro method.

[0094] Abbreviations: kDa - kilodalton; Gal - D - galactose; Gal A - D - galacturonic acid; Rha - L - rhamnose; Ara - L - arabinose; Fuc - L - fucose; Glc - D - glucose; Grac A - D - glucuronic acid. The L- and D- forms of these monomers and corresponding polymers (e.g., polysaccharides) shown herein also apply to monomers and polymers (e.g., polysaccharides) shown in the remainder of this specification (which may be written out in full without abbreviation).

[0095] The term "mean" may refer to the arithmetic mean, mode, or median. Preferably, the mean refers to the arithmetic mean.

[0096] The polysaccharide according to the present invention may be an isolated polysaccharide. The term "isolated" can refer to polysaccharides that are no longer found in their natural environment. Therefore, the term "isolated" can refer to polysaccharides isolated from Malvaceae / Malvoideae / Malveae plant tissues and cells (e.g., Sida cordifolia tissue and Sida cordifolia cells).

[0097] The "subject" may be a vertebrate, mammal, non-human animal, or domesticated animal. Therefore, the polysaccharides, adjuvants, vaccines, compositions, and pharmaceuticals according to the present invention may be used to treat any mammal, such as livestock (e.g., horses), pets, or for other veterinary purposes. Livestock may be bovines, cows, cattle, sheep, horses, birds, goats, pigs, calves, deer, geese, turkeys, or rabbits. Domesticated animals may be dogs or cats. Preferably, the subject is a mammal. Most preferably, the mammal is a human. "Organism" can mean the subject.

[0098] Modulation of the immune response is the regulation of the activity or ability of the immune system to protect the body. This may involve immunostimulation or immunosuppression. The main job of the immune system is to protect against pathogens such as fungi, bacteria, viruses, protozoa, and parasites. In this context, modification of the immune response preferably means stimulating the immune response so that it can accomplish this function. H This can be achieved by activating or enhancing an intervening response. Preferably, stimulating the immune response contributes to enhancing the body's natural defenses. On the other hand, the immune system may trigger an immune response to harmless substances such as dust mites, dust, and pollen, resulting in allergies (overactive T1). H This leads to a 2-mediated response. Furthermore, many physiological disorders, such as hypercholesterolemia and obesity, result in low-grade inflammatory states. Immunomodulation in the context of abnormal immune responses, such as allergies or inflammation, means attenuating or interfering with hypersensitive immune responses. This invention may relate to the primary task of stimulating / enhancing immune responses, and / or inhibiting “abnormal” immune responses.

[0099] The pharmaceutical composition according to the present invention may further comprise a pharmaceutically acceptable salt or other form. The pharmaceutical composition according to the present invention may comprise one or more pharmaceutically acceptable excipients such as carriers, diluents, fillers, disintegrants, lubricants, binders, colorants, pigments, stabilizers, preservatives, antioxidants, and / or solubility enhancers. The pharmaceutical composition according to the present invention may comprise a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients.

[0100] Pharmaceutical compositions can be formulated by techniques known in the art. Pharmaceutical compositions can be formulated as dosage forms for oral, non-enteral, such as topical, transdermal, intramuscular, intravenous, subcutaneous, intradermal, intra-arterial, intracardiac, nasal, inhalation, or aerosol administration (e.g., nasal or oral inhalation). Pharmaceutical compositions can be formulated as dosage forms for oral administration.

[0101] In this specification, the term "pharmaceutically acceptable salt" is intended to refer to a salt that is not harmful to the patient. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium salts, and alkylated ammonium salts. Acid addition salts include salts of organic acids and salts of inorganic acids. Representative examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfuric acid, and nitric acid. Suitable organic acids include formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, propionic acid, benzoic acid, cinnamic acid, citric acid, fumaric acid, glycolic acid, lactic acid, maleic acid, malonic acid, mandelic acid, oxalic acid, picric acid, pyruvic acid, salicylic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, ascorbic acid, pamoic acid, bismethylenesalicylic acid, ethanedisulfonic acid, gluconic acid, citraconic acid, aspartic acid, stearic acid, palmitic acid, EDTA, glycolic acid, p-aminobenzoic acid, glutamic acid, benzenesulfonic acid, and p-toluenesulfonic acid. Further examples of pharmaceutically acceptable inorganic acid additions or organic acid addition salts include the pharmaceutically acceptable salts described in J. Pharm. Sci. 1977, volume 66, issue 2. Examples of metal salts include lithium salts, sodium salts, potassium salts, and magnesium salts. Examples of ammonium salts and alkylated ammonium salts include ammonium salts, methylammonium salts, dimethylammonium salts, trimethylammonium salts, ethylammonium salts, hydroxyethylammonium salts, diethylammonium salts, butylammonium salts, and tetramethylammonium salts.

[0102] The pharmaceutical compositions according to the present invention may be formulated in accordance with prior art, such as that disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995, with a pharmaceutically acceptable carrier or diluent, as well as any other known adjuvants and excipients.

[0103] Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, and various organic solvents. Examples of solid carriers include lactose, clay, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Examples of liquid carriers include syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene, and water. Furthermore, the compounds of the present invention can form solvates with water or common organic solvents. Such solvates are also included in the scope of the present invention.

[0104] The composition may further comprise a buffer system, preservatives, isotonic agents, chelating agents, stabilizers, and surfactants, which are well known to those skilled in the art. For convenience, see Remington: The Science and Practice of Pharmacy, 20th edition, 2000. The composition may also further comprise one or more therapeutic agents active against the same disease condition.

[0105] Methods for producing release control systems useful for the compositions of the present invention include, but are not limited to, crystallization, concentration, cocrystallization, precipitation, coprecipitation, emulsification, dispersion, high-pressure homogenization, encapsulation, spray drying, microencapsulation, coacervation, phase separation, solvent evaporation producing microspheres, extrusion, and supercritical fluid processes. Generally, refer to the Handbook of Drug Release Control (Wise, DL, ed. Marcel Dekker, New York, 2000) and Drug and the Pharmaceutical Sciences vol. 99: Protein Composition and Delivery (MacNally, EJ, ed. Marcel Dekker, New York, 2000).

[0106] The pharmaceutical compositions according to the present invention may be administered via several routes of administration, e.g., oral, nasal, rectal, inhalation (e.g., nasal or oral inhalation), pulmonary, topical (including buccal and sublingual), percutaneous, intracisional, intrathoracic, vaginal, and non-enteral (including subcutaneous, intramuscular, intrathecal, intravenous, and intradermal) routes. It will be understood that the preferred route will depend on the general condition and age of the subject being treated, the nature of the condition being treated, and the active ingredient selected.

[0107] For topical use, possible applications include sprays, creams, ointments, jellies, gels, inhalants, skin patches, implants, and suspensions containing the compounds of the present invention. For the purposes of this application, topical applications include mouthwashes and gargles. The compounds of the present invention can be used in wafer technology, and wafer technology such as biodegradable gliadel polymer wafers is useful in chemotherapy for brain tumors.

[0108] Pharmaceutical compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, lozenges, sugar-coated tablets, pills, lozenges, powders and granules, as well as liquid dosage forms for oral administration, including solutions, emulsions, aqueous or oily suspensions, syrups and elixirs, each containing a predetermined amount of active ingredient and potentially containing appropriate excipients.

[0109] Compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more agents selected from the group consisting of sweeteners, flavorings, colorants, and preservatives in order to provide a pharmaceutically elegant and palatable formulation.

[0110] The tablets may contain the active ingredient mixed with non-toxic, pharmaceutically acceptable excipients suitable for the manufacture of tablets. These excipients may be inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, such as corn starch or alginic acid; binders, such as starch, gelatin, or acacia; and lubricants, such as magnesium stearate, stearic acid, or talc.

[0111] The tablets do not need to be coated, but may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing a longer-lasting effect. For example, time-delaying materials such as glyceryl monostearate or glyceryl distearate can be used. Alternatively, osmotic therapeutic tablets for controlled release can be formed by coating by techniques described in U.S. Patents 4,356,108; 4,166,452; and 4,265,874.

[0112] Oral formulations may also be presented as rigid gelatin capsules in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with a water or oil medium, such as peanut oil, liquid paraffin, or olive oil.

[0113] The aqueous suspension may contain the active compound mixed with excipients suitable for the preparation of the aqueous suspension. Such excipients include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, and acacia gum; dispersants or wetting agents (naturally occurring phospholipids such as lecithin, or condensates of alkylene oxides and fatty acids, such as polyoxyethylene stearate, or condensates of ethylene oxide and long-chain aliphatic alcohols, such as heptadecaethyl-eneoxycetanol, or condensates of ethylene oxide and partial esters derived from fatty acids and hexitol, such as polyethylene sorbitol monooleate, or condensates of ethylene oxide and partial esters derived from fatty acids and anhydrides, such as polyethylene sorbitan monooleate). The aqueous suspension may also contain one or more colorants, one or more flavorings, and one or more sweeteners, such as sucrose or saccharin.

[0114] Oily suspensions can be formulated by suspending the active ingredient in a vegetable oil, such as peanut oil, olive oil, sesame oil, or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspension may also contain thickeners such as beeswax, hard paraffin, or cetyl alcohol. Sweeteners and flavorings can be added to provide an easily digestible oral preparation. These compositions can be preserved by adding antioxidants such as ascorbic acid.

[0115] Dispersible powders and granules suitable for preparing aqueous suspensions by adding water are provided as admixtures of the active compound with a dispersant or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are already exemplified above. Additional excipients, such as sweeteners, flavorings, and colorants, may also be present.

[0116] The pharmaceutical composition of the present invention may be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil, such as olive oil or peanut oil, or a mineral oil, such as liquid paraffin, or a mixture thereof. Suitable emulsifiers may be naturally occurring gums, such as acacia gum or tragacanth gum, naturally occurring phosphatides, such as soybean, lecithin, and partial esters obtained from esters or fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensates of the partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweeteners and flavorings.

[0117] Syrups and elixirs may contain sweeteners, such as glycerol, propylene glycol, sorbitol, or sucrose. Such formulations may also contain lubricants, preservatives, flavorings, and colorings. Pharmaceutical compositions may also be in the form of sterile aqueous or oily suspensions for injection. These suspensions may be formulated according to known methods using the appropriate dispersants or wetting and suspending agents described above. Sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic, non-enterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Acceptable vehicles and solvents that may be employed may be water, Ringer's solution, and isotonic sodium chloride solution. Furthermore, sterile non-volatile oils are conveniently employed as solvents or suspension media. For this purpose, non-volatile oils of any brand may be employed using synthetic mono or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectable preparations.

[0118] Non-enteral administration may be performed by subcutaneous, intramuscular, intraperitoneal, or intravenous injection using a syringe, optionally a pen-type syringe. Alternatively, non-enteral administration may be performed by means of an infusion pump. Further options include compositions that may be solutions or suspensions for administering prolactin receptor antagonists in the form of nasal or pulmonal spray. Yet another option is that pharmaceutical compositions containing the compounds of the present invention may be adapted for transdermal administration, e.g., by needleless injection, or by patch, optionally by iontophoretic patch, or by transmucosal administration, e.g., buccal administration.

[0119] Pharmaceutical compositions for non-enteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions, or emulsions, as well as sterile powders that are reconstituted into sterile injectable solutions or dispersions before use.

[0120] Pharmaceuticals include, but are not limited to, compositions (e.g., pharmaceutical compositions or edible compositions), prescription drugs, over-the-counter drugs, commercial drugs, dietary supplements, dietary foods, clinical foods, edible products, food products such as tablets, capsules, pills and beverages, or any other suitable food products, and any other compositions commonly known to those skilled in the art. Alternatively, pharmaceuticals may be injectable substances or inhalable substances such as nasal sprays.

[0121] The polysaccharides according to the present invention may be added to edible or pharmaceutical compositions in the form of specific salts. The edible composition according to the present invention may be in any physical form. In particular, it may be a food product, a beverage, a dietary food, or a clinical food. It may also be in the form of a beverage, tablet, capsule, liquid (e.g., soup or beverage, spread, dressing or dessert), or other form of dietary supplement suitable for a dietary supplement. The edible composition may be in the form of a liquid or spread, a spoon-shaped solid or soft solid product, or a dietary supplement. Preferably, the edible composition is a liquid product. The edible product may preferably take the form of, for example, a soup, a beverage, a spread, a dressing, a dessert, or bread. As used herein, the term “spread” includes spreadable products such as margarine, light margarine, spreadable cheese-based products, processed cheese, daily spreads, and daily-alternative spreads. The spreads (oil-in-water or water-in-oil emulsions) used herein may have an oil and / or fat concentration of about 5% to 85% by weight, preferably about 10% to 80% by weight, and more preferably about 20% to 70% by weight. Preferably, the oil and / or fat may be plant-derived oils and / or fats (such as sunflower oil, palm oil, rapeseed oil, etc.), or non-plant-derived oils and / or fats (such as dairy fat, fish oil, etc.), which may also be included in the composition. The polysaccharides, and therefore edible compositions, according to the present invention may be prebiotics. A prebiotic can be defined as a composition that induces the growth and / or activity of beneficial microorganisms, such as fungi and / or bacteria, that colonize the intestines. The growth and / or activity of beneficial microorganisms may be increased by the polysaccharides acting as a substrate for the beneficial microorganisms.

[0122] The term "aqueous composition" is defined as a composition containing at least 50% w / w water. Similarly, the term "aqueous solution" is defined as a solution containing at least 50% w / w water, and the term "aqueous suspension" is defined as a suspension containing at least 50% w / w water. Such aqueous solutions are appropriately buffered as needed, and the liquid diluent should first be isotonic with sufficient saline or glucose. Aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. The sterile aqueous media used are all readily available by standard techniques known to those skilled in the art. Formulations for depot injection are also intended to fall within the scope of this invention.

[0123] An "immunological adjuvant" can refer to an agent that enhances the immune response to an antigen or vaccine.

[0124] As used herein, the terms “treatment” and “to treat” shall be understood to mean the management and care of an object aimed at combating a condition such as a disease or disorder. The term is intended to encompass the entire range of treatments for a given condition in which an object is suffering, including the reduction of symptoms or complications, the delay of the progression of a disease, disorder or condition, the reduction or mitigation of symptoms and complications, and / or the cure or elimination of a disease, disorder or condition, and the prevention of a condition, where prevention is understood to mean the management and care of an object to combat a disease, condition or disorder, and includes the administration of ligands that prevent the onset of symptoms or complications.

[0125] The term "contains" can mean "consisting of" or "essentially becoming from."

[0126] All embodiments and features described herein (including the appended claims, abstract and drawings), and / or all steps of any method or process disclosed herein may be combined with any of the above embodiments or features in any combination, unless otherwise stated by reference to a particular combination, for example, a combination in which at least some of such features and / or steps are mutually exclusive.

[0127] To better understand the present invention and to show that embodiments of the present invention can be carried out, the accompanying drawings are to be referenced as an example. [Brief explanation of the drawing]

[0128] [Figure 1] Figure 1 is a schematic diagram of an optimized extraction protocol for obtaining active arabinan polysaccharides from plant material. The flowchart shows the three main steps required for polysaccharide isolation, including methodological details. Briefly, this method involves a first step using ethanol to initially extract the polysaccharide, a second step involving up to six cycles of water (aqueous) extraction, and a final step of enzymatic digestion, dialysis, and precipitation.

[0129] [Figure 2] Figure 2 shows the elution profiles of known MW dextran (blue) and albinan Br / 17 / D (red) by size exclusion chromatography (SEC)-HPLC. Comparison with known molecular weight dextran revealed that the molecular weight of Br / 17 / D is 49 kDa. Below are examples of calibration curves based on known MW dextran, as well as examples of linear and amorphous curves.

[0130] [Figure 3] Figure 3 shows the chain analysis of Br / 14 / E (low purity fraction). It is a GC-MS analysis of partially methylated alditol acetate (PMAA) of fraction Br / 14 / E. The upper trace shows a chromatogram indicating the total ion abundance. The lower trace (red) shows a chromatogram indicating the abundance of 118 ion (extracted chromatogram ion 118) (only peaks containing this ion are shown). I = impurity.

[0131] [Figure 4]Figure 4 shows the 1H NMR spectra (600 MHz, 298 K, D2O) of (A) Br / 14 / E (low purity fraction) and Br / 18 / F (pure arabinane); and (B) magnified 1H NMR spectra of Br / 14 / E and Br / 18 / F. The structure of arabinane is shown in Figure 57.

[0132] [Figure 5] Figure 5: A) Magnified 1H NMR (600 MHz, 298 K, D2O) of arabinane (Br / 18 / F) detailing the anomeric region with integral values ​​used to evaluate the ratios between different signals. Each signal is labeled with a capital letter for use in diagnosing arabinofuranose units. B) Structure of the arabinane polysaccharide drawn according to the rules of SNFC. This structure contains the arabinofuranose units found by NMR analysis, and the ratios detected by integration are maintained as good approximations.

[0133] [Figure 6] Figure 6: Full-scale 1H-13C HSQC spectrum (600 MHz, 298 K, D2O) of Br / 18 / F (pure arabinane with strong activity). Density is labeled for quick identification, and the proton spectrum is reported in red; see Figure 57B for the structure of arabinane and the labels used. "i" indicates impurities, * indicates artifacts in the HSQC sequence.

[0134] [Figure 7] Figure 7: Magnified 1H-13C HSQC spectrum (600 MHz, 298 K, D2O) of Br 18 / F (pure arabinane with strong activity). Details include the (upper) anomeric region, (lower) carbinolic region, and proton trace. CH2 (black) is distinguished from other densities as it represents the spectrum obtained at the DEPT mode. See Figure 57B for the structure of arabinane and the labels used.

[0135] [Figure 8] Figure 8: Selected regions of the NMR spectrum (600 MHz, 298 K, D2O) reporting the overlap of the HSQC (dark gray) and HMBC (light gray) spectra of Br 18 / F (pure arabinane with strong activity): anomeric region (left panel) and carbinol region (right panel). See Figure 57B for the structure of arabinane and the label used.

[0136] [Figure 9] Figure 9: Detailed description of the anomeric region of arabinane (Br / 18 / F, pure arabinane with strong activity), with reports of overlapping TOCSY (black) and COSY (dark and light gray) spectra (600 MHz, 298 K, D2O) magnified. See Figure 57B for the structure of arabinane and the labels used.

[0137] [Figure 10] Figure 10: Magnified view detailing the anomeric region of arabinane (Br / 18 / F, pure arabinane with strong activity), reporting the overlap of NOESY (black) and COSY (dark and light gray) spectra (600 MHz, 298 K, D2O). See Figure 57B for the structure of arabinane and the labels used.

[0138] [Figure 11] Figure 11 shows the bindings important for immunomodulatory activity. Linear arabinan polysaccharides with only the 1-5 backbone lack immunomodulatory activity. Arabinan polysaccharides with both the 1-5 backbone and 1-3 branching also lack activity. The only tested arabinan polysaccharide with immunomodulatory activity is one containing 1-5, 1-3, and additional 1,2 links (18F). Measurements herein are based on NO production within macrophage cell lines.

[0139] [Figure 12] Figure 12 shows that the immunomodulatory activity of 1-5,1-3,1,2-linked arabinan polysaccharide (18F) is concentration-dependent, and NO production in macrophage cell lines significantly increases with increasing concentration.

[0140] [Figure 13] Figure 13 shows that the molecular weight of the purified 1-5, 1-3, and 1,2-linked arabinan polysaccharides can affect their activity. Different preparations of polysaccharides with the same 1-5, 1-3, and 1-2 structure but different molecular weights exhibited different levels of activity. Preparations containing polysaccharides with molecular weights of 66 kDa and 10 kDa showed strong activity (Br / 36 / A). Preparations containing polysaccharides with a molecular weight of 49 kDa showed moderate activity (Br / 17 / D). Preparations containing polysaccharides with a molecular weight of 12 kDa also showed moderate activity (18F). Finally, preparations containing polysaccharides with a molecular weight of 3 Daa showed poor, negligible activity (Br / 34F).

[0141] [Figure 14] Figure 14 is a heatmap showing the splenic cell proliferation extracts: EXH hexane extract; EXC chloroform extract; EXM methanol extract; and EXA aqueous extract. Red > Yellow > Blue

[0142] [Figure 15] Figure 15 is a heatmap showing antibody secretion (IgG) EXH hexane extract; EXC chloroform extract; EXM methanol extract; and EXA aqueous extract. Red > Yellow > Blue

[0143] [Figure 16] Figure 16 is a heatmap showing antibody secretion (IgA) EXH hexane extract; EXC chloroform extract; EXM methanol extract; and EXA aqueous extract. Red > Yellow > Blue

[0144] [Figure 17] Figure 17 is a heatmap showing antibody secretion (IgM) EXH hexane extract; EXC chloroform extract; EXM methanol extract; and EXA aqueous extract. Red > Yellow > Blue

[0145] [Figure 18]Figure 18 shows RAW 264.7 macrophages. (A) shows macrophages exposed to an aqueous (crude) extract of Sida cordifolia and then cultured in a medium containing Neural Red. Exposure to an aqueous extract of Malveae makes the cells appear much larger and increases their endocytotic capacity, resulting in a stronger red color in the cytoplasm of the cells. (B) shows macrophages treated under the same conditions but not exposed to polysaccharides, and they appeared smaller with significantly lower Neural Red intake.

[0146] [Figure 19] Figure 19 is a heatmap showing the effects of extracts (EXH hexane extract; EXC chloroform extract; EXM methanol extract; EXA aqueous extract) on respiratory bursts. Red > Yellow > Blue

[0147] [Figure 20] Figure 20 is a heatmap showing the phagochagocytosis rate of EXH hexane extract; EXC chloroform extract; EXM methanol extract; and EXA aqueous extract. Red > Yellow > Blue

[0148] [Figure 21] Figure 21 shows the results of a splenocyte proliferation assay using an extract of Sidalcea malviflora as an example: (A) IgA secretion by S. malviflora, (B) IgG production by S. malviflora, and (D) IgM production by S. malviflora.

[0149] [Figure 22] Figure 22 shows the results of a splenocyte proliferation assay and an ELISA rdU assay using S. malviflora extract.

[0150] [Figure 23]Figure 23 is a bar graph showing the % wt. of mucus in the aqueous extract of Malveae.

[0151] [Figure 24] Figure 24 shows the IR spectrum obtained from the polysaccharide precipitate M. sylvestris.

[0152] [Figure 25] Figure 25 shows a graph illustrating the proportion of monosaccharides that make up the polysaccharides of (A) Sidalceae malviflora (malveae sub malvoideae) and (B) Malva sylvesteris (malveae sub malvoideae).

[0153] [Figure 26] Figure 26 shows a graph illustrating the proportion of monosaccharides that make up the polysaccharides of (A) Malva sylvestris (malveae sub malvoideae) and (B) Sphaeralcea coccinea (malveae sub malvoideae).

[0154] [Figure 27] Figure 27 shows a graph illustrating the proportion of monosaccharides constituting the polysaccharides of the following malvacea subfamilies in which no immunomodulatory effects were observed: (A) Lagunaria patersonii (subfamily; Bombacoideae) and (B) Hibiscus rosa-sinensis (subfamily; Malboideae tribe; Hibisceae).

[0155] [Figure 28] Figure 28 is a heatmap comparing splenocyte proliferation observed in both aqueous extracts (EXA) and aqueous extract precipitates (EXAP) produced by ethanol precipitation from the aqueous extracts.

[0156] [Figure 29] Figure 29 is a heatmap comparing lymphocyte IgG production in both the aqueous extract (EXA) and the aqueous extract precipitate (EXAP) produced by ethanol precipitation from the aqueous extract.

[0157] [Figure 30] Figure 30 is a heatmap comparing lymphocyte IgA production in both the aqueous extract (EXA) and the aqueous extract precipitate (EXAP) produced by ethanol precipitation from the aqueous extract.

[0158] [Figure 31] Figure 31 is a heatmap comparing lymphocyte IgM production in both the aqueous extract (EXA) and the aqueous extract precipitate (EXAP) produced by ethanol precipitation from the aqueous extract.

[0159] [Figure 32] Figure 32 is a heatmap comparing the macrophage phagocytic activity of both the aqueous extract (EXA) and the aqueous extract precipitate (EXAP) produced by ethanol precipitation from the aqueous extract.

[0160] [Figure 33] Figure 33 is a heatmap comparing macrophage respiratory bursts for aqueous extract (EXA) and aqueous extract precipitate (EXAP) produced by ethanol precipitation from the aqueous extract.

[0161] [Figure 34]Figure 34 shows the number of blood cells per 1 ml of hemolymph in Galleria larvae. (A) S. cordiflia (B) M. sylvesteris (C) M. lateritium (D) S. malviflora

[0162] [Figure 35] Figure 35 shows the CFU / ml of larvae pretreated with polysaccharide concentrated aqueous extracts: (A) S. cordiflia, (B) M. sylvesteris, (C) M. lateritium, and (D) S. malviflora.

[0163] [Figure 36] Figure 36 shows the results of the splenocyte proliferation assay. The groups are SCAF0 (crude polysaccharide fraction of S. cordifolia); SCAF1: low ionic intensity <100kDa; SCAF2: medium ionic intensity, 10-100kDa; SCAF3: medium ionic intensity, >100kDa; SCAF4: high ionic intensity, 10kDa-100kDa; SCAF5: high ionic intensity, <100kDa; and CON A (positive control).

[0164] [Figure 37] Figure 37 shows IgG secretions from spleen cells incubated with extracts of Sida cordofilia. The groups are SCAF0 (crude polysaccharide fraction of Sida cordofilia); SCAF1: low ionic intensity <100kDa; SCAF2: medium ionic intensity, 10-100kDa; SCAF3: medium ionic intensity, >100kDa; SCAF4: high ionic intensity, 10-100kDa; SCAF5: high ionic intensity, <100kDa; and CON A (positive control).

[0165] [Figure 38]Figure 38 shows IgM secretion by splenocytes incubated with extracts of Sida cordifolia. The groups are SCAF0 (crude polysaccharide fraction of S. cordifolia); SCAF 1: low ionic intensity <100kDa; SCAF 2: medium ionic intensity, between 10 and 100kDa; SCAF 3: medium ionic intensity, >100kDa; SCAF 4: high ionic intensity, between 10kDa and 100kDa; SCAF 5: high ionic intensity, <100kDa; and CON A (positive control).

[0166] [Figure 39] Figure 39 shows IgA secretion by splenocytes incubated with extracts of Sida cordofilia. The groups are SCAF 0 (crude polysaccharide fraction of S. cordifolia); SCAF1: low ionic intensity <100kDa; SCAF2: medium ionic intensity, 10-100kDa; SCAF3: medium ionic intensity, >100kDa; SCAF4: high ionic intensity, 10-100kDa; SCAF5: high ionic intensity, <100kDa; and CON A (positive control).

[0167] [Figure 40] Figure 40 shows the results of the phagocytic assay using neutral red. The groups were: SCAF0 (crude polysaccharide fraction of S. cordifolia); SCAF1: low ionic intensity <100kDa; SCAF2: medium ionic intensity, 10-100kDa; SCAF3: medium ionic intensity, >100kDa; SCAF4: high ionic intensity, 10kDa-100kDa; SCAF5: high ionic intensity, <100kDa; and LPS (positive control).

[0168] [Figure 41] Figure 41 shows the nitrite concentrations detected in growth medium (RAW264 cells) incubated with an extract of Sida cordofilia.

[0169] [Figure 42] Figure 42 shows the tubes used for the horseshoe crab hematopoietic extract (LAL) assay. LAL is an aqueous extract of horseshoe crab hematopoietic cells that coagulates upon detection of endotoxin. The lower tube contains 2SCAF 5, and the upper tube contains LPS endotoxin. The presence of endotoxin is confirmed by the coagulation in the upper tube. However, since the blood did not coagulate even when SCAF 1-5 was added, it was confirmed that endotoxin was not present.

[0170] [Figure 43] Figure 43 shows the results of a TLR4 inhibition assay using TAK-242. The effects of the extract and TAK-242 on macrophage nitrite production were monitored. The failure to inhibit macrophage activation when cells were incubated with TAK-242 suggests that the activation pathway is not involved with the TL4 receptor.

[0171] [Figure 44] Figure 44 shows cytokine expression mediated by RAW 264.7 after exposure to SCAF5.

[0172] [Figure 45] Figure 45 shows cytokine expression by splenocytes after exposure to SCAF5.

[0173] [Figure 46] Figure 46 shows the amplification curve of iNOS after exposure to SCAF5 (RAW 264.7). The lines represent the untreated control and the treatment with SCAF5.

[0174] [Figure 47] Figure 47 shows the amplification curve of IL-6 after exposure to SCAF5 (splenic cells). The lines represent untreated control and treatment with SCAF5.

[0175] [Figure 48]Figure 48 shows the blood cell count of Galleria mellonella larvae exposed to S. cordofilia. It lists the blood cell counts per 1 ml of hemolymph after administration (24h; SCAF1-SCAF5; 100 μg / ml). LPS (1 μg / ml).

[0176] [Figure 49] Figure 49 shows the bacterial load (ACTCC 43300) 24 hours post-infection in Galleria larvae exposed to SCAF0 and SCAF5 (20 μl, 100 μg / ml). Control larvae (20 μl PBS).

[0177] [Figure 50] Figure 50 shows (1) the amount of bacteria (MRSA 43300) in the hemolymph of Galleria larvae 24 hours after treatment with PBS (colonies stained with MTT); and (2) the amount of bacteria (MRSA 43300) in the hemolymph of Galleria larvae 24 hours after treatment with SCAF5 (20 μl; 100 μg / ml). Colonies are visualized with MTT.

[0178] [Figure 51] Figure 51 shows the concentration-action curve in RAW 264.7 macrophages treated with the polysaccharide according to the present invention. The measured action was NO production.

[0179] [Figure 52] Figure 52 shows the concentration-action curve in RAW 264.7 macrophages treated with the polysaccharide or LPS according to the present invention. The measured action is NO production.

[0180] [Figure 53] Figure 53 shows the effect of the polysaccharide according to the present invention on cytokine production by macrophages.

[0181] [Figure 54] Figure 54 shows the effect of the polysaccharide according to the present invention on cytokine production by human umbilical vein endothelial cells.

[0182] [Figure 55] Figure 55 shows the effect of the isolated polysaccharides according to the present invention on the bacterial composition of feces from C57Bl / 6J mice at the phyla level.

[0183] [Figure 56] Figure 56 shows the effects of the isolated polysaccharides according to the present invention on bacterial diversity in the feces of C57Bl / 6J mice at the strain and species levels. [Examples]

[0184] Example 1 - Isolation of plant polysaccharides The active arabinan polysaccharide of the present invention can be isolated from plant material by several methods. An optimized three-step extraction process (schematically shown in Figure 1) yields the active arabinan present in Br / 29 / 16 (Br / 29 / 17 is inactive). The active arabinan present in Br / 29 / 16 is highly concentrated and relatively pure, but may be further purified by chromatography.

[0185] Process I - The initial extraction is performed by incubating the powdered plant material overnight in 95% ethanol at room temperature. The extraction is completed by centrifugation to obtain a precipitate pellet at the bottom of the tube. The remaining ethanol phase (Br / 29 / 2) is discarded.

[0186] Process II -Further extraction is performed by repeating a cycle six times in which water is added to the pellets, boiled using an oil bath and thermocouple (1 hour; 100°C), and then centrifuged (see Figure 1 for details). Each time, the aqueous phase (e.g., Br / 29 / 3, 5, 7, 9, 11, and 14) is mixed together, and the pellets at the bottom of the tube (e.g., Br / 29 / 4, 6, 8, 10, and 12) undergo further extraction cycles.

[0187] Process III- The pooled extract is reduced in volume using a rotary evaporator. This is then enzymatically digested (37°C) to remove unwanted polysaccharides and proteins (Figure 1). The added enzymes include pullulanase (EC 3.2.1.41; Sigma Aldrich), α-amylase (EC 3.2.1.1; Sigma Aldrich), and protease k (EC 3.4.21.14; Sigma Aldrich). Next, this digest is dialyzed (Spectra / Por(registered trademark)4 Dialysis Membrane Standard RC Tubing; MWCO: 12-14 kDa; Thermo Fisher), and the final polysaccharide preparation (BR / 29 / 16) is obtained by precipitation with ethanol and a final centrifugation step. This pellet has potent immunomodulatory activity.

[0188] Example 2 - Determination of the chemical structure of plant polysaccharides in the active fraction of Sida Cordofolia and optimization of the extraction / purification method. Extracts from the roots of *Sida cordofolia* were purified by gel filtration, HPLC, and other predetermined chromatographic methods. Highly purified polysaccharide fractions with bioactivity were identified by the bioactivity-inducing fractionation process. Several different extraction / purification strategies were performed, and the resulting polysaccharides were evaluated in terms of (i) activity, (ii) yield, (iii) purity, and (iv) molecular weight. Activity was determined by measuring the NO response in macrophage cell lines, as described above. Yield was determined by comparing the dry weight of the fraction with the initial dry weight. Purity was assessed as appropriate by NMR or chromatography. Molecular weight was determined by SEC-HPLC (TSK gel G5000 PWXL, 30cm x 7.8mm ID). Purified arabinan polysaccharide (30 μl; 1 mg / ml solution) was injected into a TSK column and eluted with 100% 50 mM ammonium bicarbonate (flow 0.8 ml / min). The eluate was monitored by refractive index. The columns were calibrated with dextran of known molecular weights (5 kDa, 50 kDa, 150 kDa, 410 kDa, 610 kDa), and the data were fitted using linear regression to evaluate the molecular weight accordingly (Figure 2). The purified arabinan polysaccharides with strong immunomodulatory activity underwent the following process: • Qualitative and quantitative analysis of monosaccharide components using CG-MS; • Analysis of the binding sites of monosaccharide components (see Figure 3), and • 1D and 2D NMR spectroscopy of pure polymers (see Figure 4-10).

[0189] [Table 2]

[0190] The bindings within arabinan necessary for immunomodulatory activity (based on NO production in macrophage cell lines) were identified (Figure 11). Two commercially available linear arabinan polysaccharides having only the 1-5 skeleton did not exhibit immunomodulatory activity. Similarly, commercially available arabinan polysaccharides having both the 1-5 skeleton and 1-3 branching also lacked activity. The inventors found that only arabinan polysaccharide (18F) containing 1-5, 1-3, and further 1,2 links possessed immunomodulatory activity. When the immunomodulatory activity of 1-5, 1-3, and 1,2 linked arabinan polysaccharide (18F) was investigated, it was found to be concentration-dependent, with NO production in macrophage cell lines significantly increasing as the added concentration increased (Figure 12). (All have the same 1-5, 1-3, and 1-2 glycosidic bonds and structures as described in Formulas I and II above), but different preparations of arabinan polysaccharides with different molecular weights may exhibit differences in their degree of activity. Preparations containing polysaccharides with molecular weights of 66 kDa and 10 kDa exhibited strong activity (Br / 36 / A; Figure 13). Preparations containing polysaccharides with a molecular weight of 49 kDa exhibited moderate activity (Br / 17 / D). Preparations containing polysaccharides with a molecular weight of 12 kDa also exhibited moderate activity (18F). Finally, preparations containing polysaccharides with a molecular weight of 3D exhibited poor, negligible activity (Br / 34F). The binding pattern of arabinan (Br / 14 / E, low purity fraction) was determined according to De Castro et al (2010). Briefly, the sample (0.5 mg) was dissolved in DMSO (1 mL), treated with powdered NaOH, methylated with iodomethane (300 μL), hydrolyzed (2 M TFA, 200 μL, 120°C, 2 h), carbonyl reduced with NaBD4 (5 mg), and finally acetylated with acetic anhydride (50 μL) in pyridine (100 μL).

[0191] PMAA derivatives were tested using an SPB-5 capillary column (Supelco, 30m x 0.25 id, flow rate, 0.8mL min). -1 The samples were analyzed by GC-MS using an Agilent instrument (a GC instrument consisting of an Agilent 6850 and an MS Agilent 5973) equipped with He as the carrier gas. Electron impact mass spectra were recorded with an ionization energy of 70 eV and an ionization current of 0.2 mA. The temperature programs used for all analyses were as follows: 150°C for 5 minutes, 150→280°C at 3°C / min, and 300°C for 5 minutes.

[0192] NMR acquisition parameters NMR analysis was performed using a Bruker 600 MHz NMR spectrometer equipped with a low-temperature probe, and the spectrum was recorded at 298 K. Acetone was used as an internal standard. 1 H 2.225 ppm, 13 C 31.45 ppm) and 2D spectrum ( 1 H- 1 H DQF-COSY, 1 H- 1 H NOESY, 1 H- 1 H TOCSY, 1 H- 13 C HSQC and 1 H- 13The HMBC spectra were acquired using Bruker software (TopSpin 2.0). In the homonuclear experiments, 512 FIDs of 2048 complex points were recorded with 32 scans per FID, and mixing times of 100 ms and 200 ms were used for the acquisition of TOCSY and NOESY spectra, respectively. The HSQC and HMBC spectra were acquired with 512 FIDs of 2048 complex points by accumulating 90 scans each. The spectra were processed and analyzed using the Bruker TopSpin 3 program. [[ID=...]]

[0193] Molecular weight measurement of pure arabinan Br / 17 / D The molecular weight of pure arabinan Br / 17 / D (corresponding to Br / 18 / F, see Figure 2) was measured by SEC-HPLC (TSK gel G5000 PWXL, 30 cm x 7.8 mm ID). To disclose the PM of arabinan, 30 μl (1 mg / ml solution) was injected into the TSK column and eluted with 100% 50 mM ammonium bicarbonate (flow rate 0.8 ml / min). The eluate was monitored by refractive index. The column was calibrated with dextrans of known molecular weights (5 KDa, 50 KDa, 150 KDa, 410 KDa, 610 KDa), and the data was fitted by linear regression to evaluate the molecular weight of Br / 17 / D accordingly (Figure 2, Table 3).

[0194] Table 3: Molecular weights of dextrans used for the calculation of the molecular weights of poly_1 and poly_2. Dextrans with molecular weights ranging from 5000 Da to 670000 Da were injected into the TSK column (30 μl of 1 mg / ml solution), and a calibration curve was created using the following linear equation: y = -1.3958x + 15.176. Br / 17 / D was injected into the TSK column (30 μl of 1 mg / ml solution), and the molecular weight was determined by solving the linear equation.

[0195]

Table 3

[0196] References De Castro C, Parrilli M, Holst O, Molinaro A. Microbe-Associated Molecular Patterns in Innate Immunity: Extraction and Chemical Analysis of Gram-Negative Bacterial Lipopolysaccharides. Methods Enzymol. 2010, 480, 89-115. Doi: 10.1016 / S0076-6879(10)80005-9.

[0197] Example 3 - Immunomodulatory activity of Malvaceae The inventors decided to study the immunomodulatory effects of plants from the Malvaceae family. Extracts from Malvaceae were found to induce a T H 1-mediated immune response.

[0198] method Plant materials and extraction The roots of Tilia cordata, Sparrmannia africana, Dombeya wallichii, Lagunaria patersonii, Pachira aquatic, Hibiscus syriacus, Hibiscus waimeae, Hibiscus rosa-sinensis, Pavonia spinifex, Abutilon theophrasti, and Sidalcea malviflora were collected and donated through the generosity of the Belfast Botanic Garden. The specimens of Thebroma cacoa and Lavatera arborea were generously donated by the Royal Botanic Garden in Edinburgh. The roots of Sida cordifolia were donated by Pukka herbs in Bristol. The plants used were grown from seeds of Malva sylvestris, Sphaeralcea coccinea, Gossypium hirsutum, Gossypium herbaceum, and Malvastrum lateritium, while the roots of Althea officinalis were obtained from Neal Yard Remedies in London.

[0199] Fresh plant roots were washed with isopropanol and water, then freeze-dried and stored at -20°C. The freeze-dried roots were homogenized into a fine powder using an analytical mill, and 100g of the mixture was used. Each root was sequentially immersed in n-hexane, chloroform, methanol, and ddH2O at room temperature for 24 hours. The n-hexane, chloroform, and methanol extracts were concentrated under reduced pressure using a rotary evaporator set to 45°C. The aqueous extract was centrifuged at 2000g for 15 minutes and then lyophilized. 1g of the aqueous extract was dissolved in 10-20ml of ddH2O, followed by ethanol precipitation (abs). The precipitate was separated from the lyophilized aqueous extract, pelletized by centrifugation, then lyophilized and stored at -20°C. The separated precipitate fraction was labeled with EXAP.

[0200] Lymphocyte assay Lymphocyte preparation All animal procedures were performed in accordance with the Animal Scientific Procedures (1986) and the research ethics guidelines of Queen's University, Belfast. Adult female balb / mice were supplied from the Biological Response Unit at Queen's University, Belfast, and sacrificed by cervical dislocation. The spleen was aseptically removed and placed in 5 ml of RPMI-1640 medium containing 1% penicillin-stroptomycin (Life Technologies). TM The spleen was preserved in Paisley (incomplete medium). The spleen was gently separated from the Paisley cell in 5 ml of incomplete medium using sterile forceps, removing excess fatty tissue and the splenic capsule. The spleen was then gently passed through a sterile 40 μm nylon cell strainer (BD Falcon, Oxford) using a rubber plunger from a 2 ml plastic syringe into the incomplete medium. The cell strainer was washed with 15 ml of incomplete medium to a total volume of 20 ml.

[0201] After allowing the culture medium to settle for 10 minutes, large cell clumps and debris were removed, and the supernatant was transferred to a new sterile 50 ml centrifuge tube. Next, the cell suspension was centrifuged at 300 g for 10 minutes, and the supernatant was discarded. Red blood cells were depleted for 1 minute using Sigma-Aldrich Red Blood Cell Lysing Buffer Hybri-Max (1 ml volume). Then, they were resuspended in 50 ml of RPMI 1640 Glutamax medium (complete medium) containing penicillin (100 U / ml), streptomycin (100 μg / ml), and 10% thermoinactivated fetal bovine serum (FBS). Live cells were counted using 0.4% trypan blue dye with an automated hematologist (Countess® automated hematologist, Invitrogen). Cell density was 2 x 10⁻⁶. 6 Prepare the cell concentration at 1 / ml, and seed 100 μl of the cell suspension into a 96-well (BD Falcon) microtiter plate, then divide into 2x10⁶ wells. 5 Cells were divided into cells / well. All of the above steps were performed under sterile conditions in a biological safety cabinet to prevent contamination. The cells were cultured for 72 hours at 37°C in a 5% CO2 humidified incubator.

[0202] Lymphocyte proliferation assay Splenocytes refer to any of the various types of leukocytes that make up the spleen tissue. They consist of diverse cell populations that are part of both the innate immune system and the adaptive immune system, which includes large populations of T and B lymphocytes. Logarithmic dilutions of the extract were performed using a 2 mg / ml stock solution of the extract in 1.5 ml of complete RPMI medium in Eppendorf tubes in the range of 2 mg / ml to 20 ng / ml. Final concentrations ranging from 1 mg / ml to 10 ng / ml were obtained by adding 100 μl of each dilution three times to seeded 96-well plates. Concanavalin A (5 μg / ml), isolated from Canavalia ensiformis (Sigma-Aldrich), known as a lymphocyte mitogen, was used as a positive control (Beckert & Sharkey 1970).

[0203] Splenocyte proliferation was also measured using the AlamarBlue® cell viability indicator, which utilizes the reducing function of living cells to convert resazurin to resorphin. Resazurin is a non-toxic, cell-permeable compound that turns blue upon entering cells. Resazurin is reduced to resorphin (pink / red) in living cells (Page et al. 1993). Living cells continuously convert resazurin to resorphin, thereby generating quantitative measures of viability and cytotoxicity. Following the manufacturer's instructions, a 10% (20 μl) AlamarBlue solution (Invitrogen) was used. TM (Life Technologies, Paisley, UK) was added to the cell culture medium in each well and incubated for a further 24 hours.

[0204] The optical density of each well was measured at λ570 nm using a Tecan Safire2 microplate reader (Tecan, Switzerland). The results were expressed using the growth index (PI) with the formula: PI = OD(λ570) stimulated cells / OD(λ570) unstimulated cells.

[0205] Splenocyte proliferation was further confirmed using a Bromodeoxyuridine (BrDU) assay kit (Roche Diagnostics Ltd, Sussex). Briefly, BrDU is a synthetic analog of thymidine that can be incorporated into the DNA of replicating cells. The incorporated BrDU can then be detected using a BrDU-specific antibody. The assay was performed according to the manufacturer's protocol.

[0206] Humoral immunity: Quantification of immunoglobulin secretion by ELISA. The effect of the extract on the ability of splenocytes (B lymphocytes) to regulate immunoglobulin production was evaluated using sandwich enzyme-linked immunosorbent assay (ELISA). Simply put, splenocytes were incubated with the extract. After 48 hours, the 96-well plate was centrifuged at 300g for 10 minutes, and 150 μl of supernatant was carefully aspirated from each well and transferred to another 96-well plate, where it was stored at -20°C.

[0207] ELISA plates were coated overnight at 4°C with 75 μl of goat anti-mouse IgA, IgG, and IgM antibodies (Sigma Alrich) diluted 1:1000 in 0.1 M sodium carbonate / sodium bicarbonate buffer (pH 9.4). The following day, the plates were blocked at 37°C for 2 hours with 150 μl of 1% skimmed dried milk (Marvel).

[0208] Microtiter plates (Greiner Bio-One) were coated with isotype-specific goat anti-mouse antibodies (IgA, IgM, and IgA) (Sigma-Aldrich) at a concentration of 10 μg / ml in carbonate buffer (0.1 M sodium carbonate / bicarbonate buffer, pH 9.4) and incubated overnight at 4°C. The plates were then washed twice with washing buffer (50 mM Tris, pH 8.0, 0.1 M NaCl, 0.05% Tween), and the wells were coated with 150 μl of blocking solution (1% defatted dried milk, 50 mM Tris, pH 8.0, 0.15 M NaCl). The plates were incubated at 37°C for 2 hours. The plates were then washed twice with washing solution. Finally, 75 μl of diluted cell supernatant was added to the wells of a 96-microtiter plate and incubated at 37°C for 2 hours. The supernatant was discarded, and the plates were thoroughly washed with ELISA washing solution. 75 μl of goat-produced anti-mouse IgG, IgA, and IgM antibodies (HRP-conjugated) (Sigma-Aldrich) were diluted to a concentration of 1:2000 in phosphate buffer containing 1% defatted dried milk and added to each well. The plate was incubated at 37°C for 1 hour using a plate shaker. After incubation, the plate was washed three times with ELISA washing solution, then incubated with 100 μl of horseradish peroxidase-conjugated goat anti-mouse antibody per well for 60 minutes, washed three more times, and then the plate was developed by adding a substrate solution containing 3,3,5,5'-tetramethylbenzidine (TMB) (Sigma-Aldrich) to each well. The plate was then incubated at room temperature for 10 minutes. After incubation, the reaction was stopped by adding 100 μl of 2M sulfuric acid to each well, and absorbance was measured at λ450 nm using a Tecan Safire2 microplate reader.

[0209] Macrophage (RAW 264.7) assay Macrophages are essential cellular components of the innate immune system and are found in virtually all tissues, circulating substances that are considered potentially pathogenic to the host. When potential pathogens are detected, they are activated, and dramatic changes occur in the cells. One study reported alterations in 25% of observed macrophage genes (Ehrta et al. 2001). After activation, cells become morphologically larger, exhibit increased endocytosis (ingestion and phagocytosis), and increase hydrolyzable proteins within lysosomes. While macrophages hold and eliminate potential threats, the transcription, production, and secretion of products that enable the organization of an adaptive immune response are significantly increased. Enzymes induced by activated macrophages include superoxide dismutase (which forms H2O2), NADPH oxidase (O2-), and inducible nitric oxide synthase (iNOS), an enzyme that metabolizes arginine to NO to kill microorganisms (Mosser et al. 2008).

[0210] Macrophage preparation Mouse macrophages derived from the RAW264.7 cell line were purchased from the European Collection of Cell Cultures (ECACC). These cells were cultured in 75 cm culture flasks in Dulbecco's Modified Eagle Medium (DMEM) containing 10% thermally inactivated FBS, 100 u / ml penicillin, and 100 μg / ml streptomycin. The cells were incubated at 37°C in the presence of 5% CO2. All cell culture operations were performed under sterile conditions in a biological safety cabinet to prevent contamination.

[0211] Macrophage proliferation assay Place cells in a 96-well plate in a 1x10⁶ arrangement. 5 cells ml(1x10 4Seeded at a seeding density of (cells / well). As a positive control, lipopolysaccharide (LPS) (Sigma-Aldrich), known as a macrophage activator, was used at a concentration of 1 μg / ml. The incubation time was 24 hours. The cells were cultured at 37 °C in the presence of 5% CO2, and macrophage proliferation was measured using AlamarBlue.

[0212] Measurement of nitrite concentration The induction of iNOS results in the endogenous production of nitric oxide (NO) by the conversion of L-arginine to citrulline (Murad 1998). NO is an important promoter of the inflammatory response and is produced only by macrophage activation via the standard pathway (ligation of TLR) (Mosser 2003). Since NO is highly reactive, its formation is generally measured indirectly (i.e., by measuring nitrite (NO2-), one of the two major stable non-volatile decomposition products of NO).

[0213] The concentration of nitrite (NO2-) in the medium was measured using the Griess reaction method according to the protocol provided by the manufacturer (Life Technologies, Paisley). Briefly, to measure the amount of NO2- produced, 50 μl of the medium was aspirated from each well and transferred to a sterile 96-well plate together with 50 μl of 1% sulfanilic acid (10 mg / ml) in 5% phosphoric acid. Next, this plate was incubated at room temperature for 10 minutes. Then, 50 μl of a solution containing 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride was added and incubated at room temperature for an additional 20 minutes. The concentration of NO2- was measured by colorimetric analysis at λ550 nm using a Tecan Safire2 microplate reader.

[0214] A standard solution of 0.1 M sodium nitrite (NaNO2) was serially diluted in the range of 100 - 1 μM, and the NO2- concentration was quantified using a standard curve.

[0215] Neutral red phagocytosis assay The ability to measure intracellular activity of macrophages via the Neutral Red uptake assay was described by Antal et al. (1995). A 0.1% Neutral Red (NR) (3-amino-7-dimethylamino-2-methylphenazine hydrochloride) solution was prepared by dissolving 0.1 g of Neutral Red crystals in 100 ml of sterile phosphate buffer (pH 7.2), and the solution was filtered through a syringe filter to remove insoluble crystals and ensure the homogeneity of the solution. Briefly, RAW 264.7 cells were cultured and seeded in a 96-well plate, incubated for 24 hours, and then 20 μl of sterile NR solution was added to each well (Repetto et al. 2008).

[0216] Next, the plate was incubated for a further 6 hours. The supernatant was then carefully aspirated and discarded, and the wells were washed twice with 200 μl of PBS (PBS: 1M KH2PO4, 1M K2HPO4, 5M NaCl pH 7.2). The cells were lysed by adding 100 μl of cell lysate (50% abs. ethanol, 49% deionized water, 1% glacial acetic acid), incubated the cells at room temperature for 2 hours, and measured the optical density at 540 nm using a Tecan Safire2 microplate reader.

[0217] Detection of endotoxins. Compared to proteins, endotoxins (lipopolysaccharides) are extremely stable and resistant to extreme temperatures and pH levels. Endotoxins originate from the cell membrane of Gram-negative bacteria and are bound within the matrix of the bacterial cell wall. However, as bacteria grow and divide, they continuously release endotoxin units into the environment. These endotoxin units can activate the TH1-mediated immune response independently of IFN-γ priming signals. Therefore, since LPS directly activates macrophages (Andrade et al. 2003) and leads to the release of inflammatory mediators such as TNFα, IL-6, and IL-1, the presence of lipopolysaccharides in extracts should be eliminated.

[0218] Exposure of Limulus spp. blood to endotoxin induces coagulation (Bang & Frost 1953), a mechanism that captures and immobilizes bacteria, preventing their systemic spread. This discovery forms the basis of the horseshoe crab hemocyte extract (Limulus Amebocyte Lysate, LAL) assay (Young et al. 1972), in which exposure of amoeboid cell lysate to endotoxin initiates an enzyme cascade culminating in the activation of coagulation enzymes, leading to the cleavage of coagulogens (coagulation proteins), resulting in the formation of insoluble coagulins, which then aggregate to form thrombi (Levin & Bang 1964).

[0219] LAL assay The Pyrosate® (CapeCod) Rapid Endotoxin Detection Kit (0.03 endotoxin units (EU) / ml) is a highly sensitive detection method. This kit is specific to endotoxins at glucan concentrations up to 100 ng / ml. The assay was performed according to the manufacturer's protocol. Briefly, a 1 mg / ml lyophilized aqueous extract was dissolved in sterile water (Sigma) free of endotoxins, and the stock solution was further diluted to produce a 100 ng / ml solution. Then, 0.5 ml of the 100 ng / ml solution was dispensed into a tube containing 0.5 ml of lyophilized LAL reagent containing only the aqueous extract of L. polyphemus amoeba-like cells, salt, glucan blocker, and buffer. Next, the test tubes were gently mixed horizontally for 20-30 seconds, and then 2.5 ml was transferred to a tube containing the control standard endotoxin (E. coli O113:H10). Next, the tubes were gently mixed again on a horizontal surface for 20-30 seconds, and then incubated at 37°C for 1 hour.

[0220] In vitro immune model (Galleria mellonella larvae) Many important aspects of the innate immune response to microorganisms are remarkably conserved between arthropods and rodents. This striking homology in immune responses has led to considerable interest in using insects as archetypal models for studying host-microbe interactions (Hultmark 1993). Arthropods are a highly economical and more ethically acceptable alternative to gnathostomes. The larvae of the honey moth Galleria melonella (lepidoptera) also have the advantage of thriving at an optimal temperature of 37°C and are ideal for culturing various pathogenic microorganisms known to infect the brown planthopper (Ramarao et al. 2012).

[0221] In arthropods, the detection of PAMPs stimulates an innate immune response via the hemolymphatic system. In the genus Galleria (spp.), as in other arthropods, the immune response involves both humoral and cellular responses (Vilmos & Kurucz 1998). The humoral response involves the production of small antimicrobial peptides and an enzyme-mediated coagulation cascade, which is the same as previously described for the genus Limulus (spp.) (Muta & Iwanaga 1996). The hemolymph of lepidopteran larvae mainly contains granule cells and plasma cells (Lavine & Strand 2002), which respond to the detection of PAMPs by mitigating the potential threat or eradicating it via phagocytosis (Schmit & Ratcliffe 1977). Interestingly, these cells also exhibit receptors similar to those found in phagocytic cells of gnathostomes (Vilmos & Kurucz 1998).

[0222] Galleria Melonella Galleria melonella larvae (Livefoods Direct) were reared on artificial feed at 25°C (darkness) and kept in sterile petri dishes (5 cm) in a 37°C incubator during the experiment. The experimental group consisted of 10 larvae (final instar) weighing 250-300 mg.

[0223] Bacterial load in larvae pre-exposed to an aqueous extract of Malveae Aqueous extracts of Sida cordifolia, Malva sylvestris, Malvastrum lateritium, and Sidaalcea malviflora were prepared aseptically in PBS at concentrations of 1 mg / ml and 0.1 mg / ml. Using a Terumo Myjector 1 ml 29 G 0.33 x 12 mm, 10 μl aliquots of the extracts were injected into the hemocoel of the larvae of each group via the propodus (left) on the dorsolateral side. Negative control groups were injected with PBS (150 mM NaCl; 5 mM KCl, pH 6.9 in 0.1 M Tris-HCl), and the larvae were placed in an incubator set to 37°C for 24 hours. Next, each group was infected with either MRSA (ATCC43300) or Escherichia coli (ACTCC11303). Inoculation experiments were performed according to the protocol described by Ramarao et al. The density of the inoculum was standardized to the optical equivalent of the 0.5 McFarland turbidity standard, which has an absorbance of 0.06-0.10 nm at λ600 nm and corresponds to 107 cfu / ml (Andrews 2001). It was further diluted with PBS (1:10) and the inoculum was administered via the prolegs (right) on the dorsolateral side in the same manner as for aqueous extracts. The inoculated larvae were kept in an incubator set to 37°C for 24 hours.

[0224] The size of the bacterial inoculum was determined using the Misra method (Miles and Misra Method, Miles et al. 1938), which involves serially diluting the bacterial inoculum, plating 20 μl of each dilution onto a Mueller-Hinton agar plate, and incubating at 37°C for 24 hours. Therefore, the inoculum concentration was 1.2 x 10⁻⁶. 6 CFU was calculated as CFU / ml. Three larvae were taken from each group at 24, 48, and 72 hours after inoculation, and the amount of bacteria in the hemolymph was measured using the Mitsra method to calculate the CFU.

[0225] Immune response The effects of Malveae extracts on blood cells were evaluated by injecting aqueous extracts of Sida cordifolia, Malva sylvestris, Malvastrum lateritium, and Sidaalcea malviflora at concentrations of 1 mg / ml and 0.1 mg / ml. Larvae were then incubated for 24 hours at 37°C. After incubation, hemolymph was removed and blood cells were counted using a hemocytometer.

[0226] Analysis of polysaccharides The presence of polysaccharides in the alcohol precipitate was confirmed using Molisch reagent (5% thymol dissolved in alcohol (abs.)). Briefly, 10 mg of the sample was dissolved in 750 μl of ddH2O in a glass test tube, 500 μl of Molisch reagent was added to the glass test tube, and then 3 gtt of concentrated sulfuric acid was added.

[0227] Measurement of protein content in polysaccharide concentrate fractions Methods for precipitating polysaccharides can also precipitate proteins. Therefore, it was necessary to measure the protein content in the precipitate. Numerous methods have been developed to measure the protein content in physiological fluids obtained from animal sources, but unfortunately, these assays are based on protein-copper chelation, which results in the reduction of copper from Cu(II) to Cu(I) and can be affected by the presence of reducing agents present in plant extracts (Compton & Jones 1985). On the other hand, the Bradford assay is based on the formation of a complex between the Brilliant Blue G250 (Coomassie Brilliant Blue) dye and basic amino acid residues (arginine, lysine, and histidine). The resulting complex shifts the absorption maxima of Brillant Blue G250 to λ465nm~595nm (Bradford 1976).

[0228] Briefly, the polysaccharide concentrate was dissolved in PBS (0.5 mg / ml), and 10 μl of the 0.5 mg / ml fraction was dispensed into the wells of a 96-well plate three times. 250 μl of Bradford reagent (Bio-Rad) was then added at room temperature. A 1 mg / ml bovine serum albumin (BSA) (Sigma Aldrich) protein standard in PBS was then serially diluted (1:10) to form standards ranging from 0 to 100 μg / ml. 10 μl of this standard was added to the wells of the 96-well plate along with the sample three times, followed by the addition of 150 μl of Bradford reagent. The plates were incubated at room temperature for 20 minutes, and the absorbance at λ595 nm was measured using a Tecan Safire 2 microplate reader (Tecan, Switzerland).

[0229] Infrared Spectroscopy Raman-IR spectroscopy (Thermo Scientific Nicolet iS5 FT-IR Spectrometer with Omnic Software) TM (Madison, Wisconsin, USA) was performed, followed by 400MHz Bruker NMR (Billerica, MA, USA) in MeOH. 13 1C NMR and 1 The structure was confirmed by 1H NMR.

[0230] GC-MS analysis of polysaccharides The polysaccharide concentrate (100 mg) was hydrolyzed in a 25 ml sealed flask with 10 ml of 1 M trifluoroacetic acid (TFA) (Sigma-Aldrich) at 105 °C for 7 hours (Uzaki & Ishiwatari 1983), and then lyophilized. Subsequently, the sample (2 mg) was derivatized by silylation with 500 μl of N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) and 1% trimethylcrosilane (Sigma-Aldrich) in 1 ml of anhydrous pyridine. The reaction was carried out at room temperature for 12 hours.

[0231] GC-MS analysis was performed using a ZB semi-volatile column (30m x 0.25mm x 0.25μm Zebron TM Gas chromatography (Agilent 7890A) connected to a mass-selective detector (Agilents 5975C) equipped with a Henomenex Inc. system was performed at a constant rate of 1 ml / min using helium as the carrier gas. The syringe and MS source temperatures were maintained at 260°C and 230°C, respectively. The column temperature program involved injecting at 80°C, holding for 1 minute, and then reducing the temperature by 15°C min. -1 The procedure involves raising the temperature to 300°C and then maintaining it isothermally at 300°C for 15 minutes. The MS was operated in electron shock mode with an ionization energy of 70 eV. The scan range was set from a mass scan range of 50 to 550 Da. The injection volume was 1 μl, and the inlet diversion was 20 ml. -1 (The division ratio was set to 20:1.)

[0232] Data acquisition and processing were performed using Chemstation software (Hewlett Packard). Compound identification was performed by chromatographic retention characteristics, mass spectra of standard substances, and comparison with the NIST mass spectrum library (National Institute of Standards and Technology, USA) (Magalhaes et al. 2007).

[0233] result Spleen cell proliferation The results of proliferation assays performed using splenocytes were summarized in a heatmap (Figure 14). The results showed that crude aqueous extracts of the Malveae family of malvoideae significantly stimulated splenocyte proliferation in a concentration-dependent manner from 0.01 to 1 mg / ml (P<0.05). This activity was observed in all eight species representing different genera of the Malveae family (subfamily Malvoideae). Splenocyte proliferation was also observed in aqueous extracts of the Gossypieae family and one species of the Hibisceae family (Abelmoschus moschatus). No activity was observed with extracts of n-hexane, chloroform, or methanol, suggesting that this activity is due to the highly polar components. The splenic cell stimulating activity observed in this assay was subsequently confirmed by the BrdU assay (Figure 14), and a similar concentration-dependent effect was observed with aqueous extracts of Malveae.

[0234] antibody secretion When splenocytes were incubated with malvaceae extracts, the supernatant collected from the wells showed a 2-3 fold increase in all IgG levels after incubation with aqueous extracts of all malveae species at a concentration of 1 mg / ml (Figure 15), and a 1-2 fold increase after incubation with aqueous extracts of all malveae species at a concentration of 0.1 mg / ml. Furthermore, a 1.2-1.5 fold increase in total IgG levels was detected in the supernatants incubated with 0.01 mg / ml concentrations of Sida cordifolia, Sidalcea malviflora, and Althaea officinalis (Figure 21). A similar trend was observed for total IgM levels after incubation, with IgM levels increasing 2-3 times at a concentration of 1 mg / ml and 1.3-2.5 times at a concentration of 0.1 mg / ml (Figure 21). The total IgM levels are summarized in the heatmap in Figure 17. Total IgA in the supernatant aspirated from wells exposed to aqueous extract of Malveae increased 1.2-1.7 times at a concentration of 1 mg / ml. The total IgA levels are summarized in the heatmap in Figure 16.

[0235] Macrophage activation Macrophage proliferation was observed by performing a proliferation assay with RAW 264.7 macrophages. Although proliferation was not observed, morphological changes typical of macrophage activation were observed (Figure 18). Cells incubated with an aqueous extract of Malveae appeared much larger and more homogeneous compared to cells without the extract (negative control). This is consistent with activated macrophages, because the number of cell membrane protrusions and vacuoles for phagocytosing internalized pathogens increases, which collectively increases the cell size.

[0236] Breathing burst Activated macrophages release reactive oxygen species and reactive nitrogen species. Nitrate, which rapidly forms nitrite ions (NO2-), is one of the nitrogen species that increases the production of reactive species essential for the degradation of parasites taken up by macrophages. The heatmap in Figure 19 shows the NO2 levels when spleen cells are incubated with extracts. - This summarizes the response in the generation of NO2. Nitrite levels followed a similar trend to previously reported splenocyte proliferation and IgG, IgM, and IgA levels. In summary, NO2 was generated when macrophages were incubated with an aqueous extract of the malveae species at a concentration of 1 mg / ml. - The levels were in the range of 60–80 μmol / ml, which was the same as for LPS at a concentration of 1 ng / ml. This activity was also statistically significant at a concentration of 0.001 mg / ml, where detectable nitrate levels were found to be in the range of 10–20 μmol / ml (P < 0.05).

[0237] phagocytosis A further characteristic of activated macrophages is their phagocytic ability. Macrophages were exposed to an aqueous extract of Sida cordifolia (malveae). After incubation, neutral red solution was added and incubated for 6 hours. NO2 - Cells that appeared to have increased levels also seemed to have darker red cytoplasm, reflecting their phagocytic capacity. When the supernatant was aspirated and the cells were lysed with a lysate, it was observed that the phagocytic activity increased twofold when the cells were incubated with an aqueous extract of Malveae, as summarized in heatmap Figure 20.

[0238] Analysis of viscous substances (mucialgenous matter) in aqueous extracts of Malveae. Aqueous extracts were freeze-dried, and the viscous substance was extracted with ethanol. The precipitate was collected, freeze-dried, and quantified. It was found that the mucus content in the aqueous extracts of the tested Malveae ranged from 12% to 24% (Figure 23).

[0239] Analysis of polysaccharide concentrate fraction (EXAP) The presence of viscous polysaccharides in the ethanol precipitate was first confirmed by the Molisch test. The presence of polysaccharides was confirmed by observing the immediate formation of a pink / purple menisce at the interface between the thymol solution and the aqueous solution after the addition of concentrated H2SO4. No color change was observed in the Lugol solution, suggesting the absence of starch. Negative results were also observed for reducing sugars using Benedict's reagent. The presence of polysaccharides in the lyophilized precipitate was subsequently confirmed by infrared spectroscopy. Figure 24 shows the spectrum of the amorphous polysaccharide precipitate, representing the IR spectrum produced by ethanol precipitation of an aqueous extract of Malvaceae. In summary, the maximum value observed in the 3380 cm⁻¹ region represents an OH group, the maximum value observed in the 2930 cm⁻¹ range indicates the presence of -CH₂ or -CH₂,HC=O, and the maximum value observed in the 1650–1700 cm⁻¹ region indicates the presence of a C=O group, overlapping with the maximum value representing C=C. In all IR spectra, maximum values ​​at 930 and 615 cm⁻¹, which are typically associated with the sugar cycle, were also observed. Typically, in all spectra, there was a region between 1200 and 1000 cm⁻¹ dominated by sugar ring vibrations where stretching vibrations due to the presence of C-OH side groups and COC glycosidic bond vibrations overlap.

[0240] Protein content in polysaccharide concentrate (EXAP) Since ethanol precipitation of polysaccharides can induce protein precipitation, the Bradford assay was used to measure protein concentrations. Protein content was measured in the range of 0–0.1 μg / ml in a solution of 1 mg ml of precipitated polysaccharide (i.e., <0.0001% w / v).

[0241] GC-MS analysis of polysaccharide precipitates (EXAP) Hydrolyzed polysaccharides were freeze-dried, derivatized, and then subjected to GC-MS analysis to identify the monosaccharides constituting the polysaccharides using standards and the NIST library. There were clear differences in the monosaccharide profiles between the malveae family and members of subfamilies that did not exhibit immunomodulatory activity. In summary, malveae polysaccharides contained a greater variety of monosaccharides, totaling nine different monosaccharides in all cases. Generally, malveae polysaccharides consisted of rhamnose (8-18%), glucose (16-28%), mannose (5-12%), arabinose (2-9%), galactose (28-1%), and uronic acid (1-14%) (Figures 25, 26), but polysaccharides isolated from aqueous extracts of other subfamily species had different compositions (Figure 27).

[0242] Endotoxin detection by LAL test Contamination of Gram-negative bacteria with lipopolysaccharide (endotoxin) was determined by the LAL test. The endotoxin level in the aqueous extract and alcohol precipitate of Malveae was 0.03 EU / ml, which is negligible.

[0243] Immunomodulatory effects of polysaccharide concentrate (EXAP) The freeze-dried precipitate of Malveae, which showed trace amounts of protein and was negative for endotoxin, was tested together with the crude aqueous extract from which it was derived.

[0244] Effects of EXAP on splenic cell proliferation, immunoglobulin secretion, and macrophage activation The aqueous extract of Malveae (EXA) showed similar responses to those previously described for splenic cell proliferation, immunoglobulin secretion, and macrophage activation. However, polysaccharide precipitation (EXAP) showed a significant improvement in activity compared to EXA. Greater splenic cell proliferation was observed with EXAP compared to EXA (Figure 28). More IgG, IgM, and IgA secretion was also observed with EXAP compared to EXA (Figures 29, 30, and 31). Macrophage activation was also greater with EXAP compared to EXA in both phagocytic activity and NO2- production. This indicates that this physiological activity was enhanced when the polysaccharide was concentrated (Figures 32 and 33).

[0245] Consideration In this study, the inventors confirmed that extracts from plants of the malvaceae family induce immunomodulatory activity in vitro and in vivo. They also identified the main components of the extracts. A variety of plants representing the broader malvaceae family were screened for their ability to activate elements of the innate and adaptive immune systems. Aqueous extracts from the malveae tribe of the malvaceae family enhanced the function of mouse lymphocytes, as evidenced by the induction of proliferation and antibody secretion. Aqueous extracts from malveae species also enhanced the phagocytic and respiratory burst activity of macrophages. The immunomodulatory activity appears to be caused by polysaccharide components of malveae, which induce immunomodulation in a simple in vivo model. Most promisingly, pretreatment of larval hosts with malveae extracts made them substantially resistant to potentially lethal microbial challenges. Since the rise of antibiotic resistance, one of the most promising alternatives to prophylactic antibiotics is the use of immunomodulators containing plant-derived exogenous biological response moduli (EDBRMs). EDBRMs are chemically diverse, including steroidal lactones, phenylchromones, triterpenoids, and bis-benzylisoquinolines, but the most prominent group to emerge chemically as EDBRMs are polysaccharides. The proposed mechanism by which plant-derived polysaccharides elicit immunomodulatory responses is by inducing one or more of the diverse pattern recognition receptors expressed by the immune system.

[0246] We found that immunomodulatory activity was present only in the aqueous extract and completely absent in the hexane, chloroform, and methanol extracts. This indicates that the active component is inherently polar. We considered the possibility that the activity was a result of endotoxin contaminants from Gram-negative bacteria, which can commonly contaminate biological samples. The presence of endotoxin contaminants was immediately ruled out by LAL assay. Ethanol precipitation isolated a light brown precipitate from the aqueous extract, which was confirmed to be the source of this immunomodulatory activity. The Molisch test showed the presence of polysaccharides, which was confirmed by IR spectroscopy. We found that the protein content of the EXAP fraction was negligible and unlikely to be involved in the immunomodulatory activity. The total polysaccharide content (% wt.) of the aqueous extract correlated with the immunomodulatory activity observed for the Malveae family as a whole. The polysaccharide profiles of the Malveae family demonstrate that they contain the same nine monosaccharides, and although there are some differences in their ratios, this does not substantially affect the immunomodulatory activity. However, non-immunomodulatory species from the same Malvoideae subfamily had entirely different monosaccharide profiles. For example, Hibiscus rosa-sinensis had only six monosaccharides, 96% of which consisted of just three sugars: glucose (67%), galactose (21%), and arabinose (8%). This is far less diverse than, for example, Sidalcea malviflora, which contains glucose (22%), arabinose (8%), rhamnose (18%), ribose (2%), xylose (1%), galacturonic acid (1%), galactose (28%), mannose (6%), and uronic acid (14%). Similarly, Lagunaria patersonnii, a subfamily of Bombacoideae that lacked activity, also exhibited far less diversity in its monosaccharide profile.Only six monosaccharides are present, and 94% of the total monosaccharide content consists of only three sugars: glucose (33%), galactose (50%), and galacturonic acid (9%). The monosaccharide composition of polysaccharides is crucial for their immunomodulatory activity. Most plant-derived polysaccharides are thought to modulate the immune system through macrophage activation (Schepetkin & Quinn 2006). The results of this example demonstrate the ability of polysaccharides isolated from Malveae to activate several macrophage functions in vitro. The concentration-dependent release of NO by activated macrophages suggests that macrophages are activated symmetrically, as alternatively activated macrophages do not induce iNOS. Furthermore, symmetric activation of macrophages activates the immune system. H This strongly suggests that these are effector cells that induce a 1-mediated response. As a result, bactericidal activity against bacteria, fungi, protozoa, and viruses is generally activated. These responses lead to macrophage activation, which in turn leads to the production of reactive oxygen species and reactive nitrogen species induced by iNOS, and the increase in the pinocytic rate observed in this example. Once activated, macrophages then... H 1. The cells begin to secrete cytokines that induce an immune-mediated response, and at this point, naive CD4+ T cells... HThese cells differentiate into 1-effector cells, resulting in the secretion of pro-inflammatory cytokines. These pro-inflammatory cytokines then initiate the activation of a more specific adaptive immune response in gnathostomes. For example, macrophage activation leads to the expression of B7-1 (CD80) and B7-2 (CD86) proteins, which function as cost-stimulating signals essential for the activation of T lymphocytes (CD8+), a crucial component of the adaptive immune response. Galleria mellonella larvae were used as a primitive arthropod model to study the stimulation of innate immunity in arthropods, as they also possess the ability to detect highly conserved PAMPs. Using this larval model, we demonstrated the stimulating effect of polysaccharide-enriched fractions from the Malveae family on the innate immune response. This was evident from the increase in blood cells (Figure 34) and the decrease in infection resistance and bacterial load of Galleria larvae (Figure 35), given that the polysaccharide concentrate fraction was shown to have no direct antibacterial activity (≤16 mg / ml). Therefore, the only plausible explanation for the observed decrease in bacterial load is the direct activation of the innate immune system. H The characteristic features of the 1-effector cells are the cytokines TNF-α and IFN-γ. TNF-α is involved as an essential factor in wound healing. It induces fibroblast proliferation and angiogenesis. This may explain why the genus Malveae has traditionally been used as a wound healing promoter. IFN-γ, on the other hand, induces B-cell production of antibodies for opsination and complement binding reactions. The increase in immunoglobulins (IgG, IgM, and IgA) in this embodiment may be a result of improved IFN-γ levels. The increased total antibody levels and stimulation of the innate immune response may be the reason why the genus Malveae has traditionally been used for its associated antitoxic effects.

[0247] Finally, it is noteworthy that Malveae polysaccharides isolated from a Malveae aqueous extract showed a very potent effect on the proliferation of mouse splenocytes, which consist of B cells (50-60%), T cells (30%), and macrophages (5%). Since proliferation was not observed in proliferation assays using macrophage cell lines (RAW 264.7), it is thought that the changes in population size were most significant in B cells and T cells.

[0248] conclusion Plant-derived polysaccharides are relatively non-toxic and tend not to induce anaphylaxis associated with polysaccharides of microbial sources. In this example, a polysaccharide isolated from the Malveae species exhibits remarkable immunomodulatory activity, which stimulates antigen-presenting cells and the associated T11 H It has been proven that this may lead to the promotion of one pathway. H Activation of one pathway promotes increased biocidal activity, which helps to rapidly eliminate infection. This ability was validated by in vivo bacterial challenges in arthropod models of the innate immune system. This reveals that plants of the Malveae subfamily can be used for the prevention or resistance of bacterial infections, and may themselves possess considerable therapeutic potential.

[0249] Example 4 - Immunomodulatory activity of Sida cordifolia The inventors fractionated and characterized a polysaccharide-concentrated fraction from an aqueous extract of Sida cordifolia. They performed bioactivity-inducing fractionation of the polysaccharide, identified some of the monosaccharides, and explored the effect of the purified extract on Toll-like receptor-4 (TLR4). They found that the purified extract did not activate the TLR4 pathway.

[0250] method Extraction of plant materials The root of Sida cordifolia L was collected in Karnataka, India (2012), donated by Pukka Herbs, Bristol, and the voucher specimen was deposited at DBN Economic Collections, Glasnevin Herbarium Dublin (DBN 06:201261). The roots of the plant were washed with isopropanol and water. The freeze-dried roots were homogenized into fine powder using an IKA® A11 analytical mill (IKA® Werke GmbH & Co. KG, Staufen, Germany). The powder (200 g) was successively soaked in n-hexane, chloroform, methanol and ddH2O at room temperature for 24 h. The n-hexane, chloroform and methanol extracts were concentrated under reduced pressure using a rotary evaporator set at 45 °C, and the aqueous extract was centrifuged at 4500 rpm for 15 min and then freeze-dried. The extracts were weighed to 0.092 g, 54.32 g, 16.4 g and 62.2 g, respectively. The polysaccharides in the freeze-dried aqueous extract (62.2 g) were extracted from the freeze-dried aqueous extract by dissolving in 20 ml of ddH20 per 10 g and then performing ethanol precipitation (abs.) (1:4 v / v) overnight. The resulting precipitate was pelleted by centrifugation and the supernatant was discarded. The yield of the freeze-dried pellet was 2.356 g (23.56% of the freeze-dried aqueous extract).

[0251] Fractionation of polysaccharides The crude polysaccharide fraction (2.00 g) obtained above was further fractionated on a DEAE TM Sephadex A-50 (weak anion exchanger) (GE Healthcare) column (30x2.5). Elution was carried out stepwise using NaCl solutions of low (0 mol / l), medium (0.75 mol / l) and high (2 mol / l) NaOH with increasing ionic strength. The fractions obtained were freeze-dried and weighed, giving 0.089 g, 0.251 g and 1.412 g, respectively. The fractions were Vivaspin TMFurther fractionation was performed according to molecular size using a molecular weight cutoff (MWCO) filter (Sartorius, Goettingen, Germany). Briefly, the lyophilized extract was dissolved in ddH2O at a concentration of 50 mg / ml, loaded onto a 100 kDa MWCO filter, and centrifuged (2000 g; 1 hour). The residue remaining on the 100 kDa MWCO filter was collected in a 1.5 ml Eppendorf tube by dissolving in water (200 μl) and rinsing (100 μl). This procedure was repeated for all ion exchange chromatography fractions (low, medium, and high). Elutions from the 10 kDa MWCO filter were collected but discarded once it was confirmed that all were inert.

[0252] The fractions obtained in the above process are as follows: SCAF0 (crude polysaccharide fraction of S. cordifolia); SCAF1: low ionic strength, <100kDa (56.1mg); SCAF2: medium ionic strength, 10-100kDa (142.6mg); SCAF3: medium ionic strength, <100kDa (72.5mg); SCAF4: high ionic strength (2mol / l), 10kDa-100kDa (532.6mg); and SCAF5: high ionic strength, <100kDa (786.7mg).

[0253] Preparation of lymphocytes All animal procedures were performed in accordance with the Animal Science Procedures (1986) and the research governance policies of Queen's University Belfast. Adult female balb / mice were supplied from the Biological Response Unit at Queen's University Belfast and sacrificed by cervical dislocation. The spleen was aseptically removed and stored in 5 ml of RPMI-1640 medium containing 1% penicillin-streptomycin or without fetal bovine serum. The spleen was gently dissected in 5 ml of medium, and excess adipose tissue and the splenic capsule were removed using sterile forceps. The spleen was pressed into RPMI1640 medium using a sterile 40 μm nylon cell strainer to prepare a lymphocyte cell suspension. Live cells were counted using 0.4% trypan blue with an automated hematologist (Countess® automated hematologist, Invitrogen). Cell density was 2 x 10⁶ 6 The cell concentration was adjusted to cells / ml. 100 μl of cell suspension was used for seeding in 96-well (BD Falcon) microtiter plates, resulting in 2 x 10⁶ cells. 5 The number of wells was / well. All of the above was carried out under sterile conditions for 72 hours in a 37°C, 5% CO2 humidified incubator in a biological safety cabinet to prevent contamination.

[0254] Lymphocyte proliferation assay Logarithmic dilutions of S. cordifolia fractions SCAF0-SCAF5 were performed using a 2 mg / ml stock solution of the extract in RPMI medium containing 10% fetal bovine serum, ranging in concentration from 0 ng / ml to 2 mg / ml. Each dilution (100 μl) was added three times to a seeded 96-well plate to obtain a final concentration of 1 mg / ml to 10 ng / ml. Concanavalin A (5 μg / ml), isolated from Canavalia ensiformis (Sigma-Aldrich), known as a lymphocyte mitogen, was used as a positive control (Beckert & Sharkey 1970). Splenocyte proliferation was measured using AlamarBlue. 10% (20 μl) AlamarBlue solution (Invitrogen) was used according to the manufacturer's instructions. TM (Life Technologies, UK) was added to the cell medium in each well and incubated for a further 24 hours. The optical density of the wells was measured at λ570 nm using a Tecan Safire2 microplate reader (Tecan, Switzerland). The results are shown using the growth index (PI) with the formula: PI = OD(λ570) stimulated cells / OD(λ570) unstimulated cells.

[0255] Humoral immunity, quantification of immunoglobulin secretion by ELISA The effects of polysaccharide fractions SCAF0 to SCAF5 on the ability of splenocytes (B lymphocytes) to regulate immunoglobulin production were evaluated using a sandwich enzyme-linked immunosorbent assay (ELISA). Briefly, splenocytes were incubated with the extract. After 48 hours, the 96-well plates were centrifuged at 300 g for 10 minutes, then 150 μl of the supernatant was carefully aspirated from each well and transferred to another 96-well plate and stored at -20 °C. ELISA assays were performed for IgA, IgG, and IgM antibodies. After incubation was complete, the plates were washed three times with an ELISA wash solution, and the plates were further incubated with 100 μl per well of horseradish peroxidase-conjugated goat anti-mouse for an additional 60 minutes. After further washing, the plates were developed by adding a substrate solution containing 3,3,5,5'-tetramethylbenzidine (TMB) (Sigma-Aldrich) to each well. The reaction was stopped by adding 100 μl of 2 M sulfuric acid per well, and the absorbance (λ450 nm) was measured using a Tecan Safire2 microplate reader.

[0256] Cell culture (RAW264.7) Mouse macrophages derived from the cell line RAW264.7 were purchased from the European Collection of Cell Cultures (ECACC). These cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated FBS, 100 u / ml of penicillin, and 100 μg / ml of streptomycin in a 75 cm 2 culture flask. The cells were incubated at 37 °C in the presence of 5% CO2. All cell culture work was performed aseptically in a biological safety cabinet to prevent contamination.

[0257] Macrophage proliferation assay The cells were incubated with fractions of S. cordifolia fractions SCAF0 to SCAF5 at concentrations ranging from 1 mg / ml to 10 ng / ml, at 1 x 10 5 cells / ml (1 x 10 4Cells were seeded in 96-well microtiter plates at a seeding density of (cells / well). Lipopolysaccharide (LPS) (Sigma-Aldrich) (1 μg / ml), a known macrophage activator, was used as a positive control. Plates were incubated (5% CO2; 37°C; 24 hours) and macrophage proliferation was observed using AlamarBlue (Invitrogen). TM Measurements were taken using Life Technologies, Paisley, UK.

[0258] Measurement of nitrite concentration To measure the amount of NO2 produced, after incubation, 50 μl of culture medium was aspirated from each well of a 96-well microtiter plate and transferred to a new 96-well microtiter plate. A solution of 50 μl of 1% sulfanilic acid in 5% phosphoric acid was added, and the mixture was incubated at room temperature for 10 minutes. Subsequently, 50 μl of a solution consisting of 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride was added, and the mixture was incubated at room temperature for a further 20 minutes. The concentration of NO2- was measured by colorimetric analysis (λ550 nm) using a Tecan Safire2 microplate reader. Serial dilutions (1–100 μM) were prepared using standard 0.1 M sodium nitrite (NaNO2), and NO2- was quantified by standard curves.

[0259] Neutral Red Phagocytic Assay A 0.1% neutral red (NR) solution was prepared by dissolving 0.1 g of NR crystals in 100 ml of sterile phosphate buffer (pH 7.2). Next, the solution was filtered using a syringe filter to remove insoluble crystals and ensure homogeneity. The assay was performed as described in Example 3. After incubation (24 hours) in fractions SCAF0 to SCAF5 (1 mg / ml to 0.1 ng / ml), 20 μl of 0.1% NR solution was added to the wells and incubated (6 hours). The supernatant was carefully aspirated and discarded, and the wells were washed twice with 200 μl of PBS. Cells were lysed by adding 100 μl of cell lysate (50% abs. ethanol, 49% deionized water, and 1% glacial acetic acid), incubated at room temperature (2 hours), and the optical density (540 nm) was measured using a Tecan Safire2 microplate reader.

[0260] LAL assay (endotoxin detection) The assay was performed according to the protocol provided by the manufacturer Pyrosate® (CapeCod), as described in Example 3.

[0261] TLR4 Inhibition Assay TAK-242 (Resatorvid) TAK-242 is a small molecule that is a specific inhibitor of Toll-like receptor (TLR) 4. It inhibits the production of pro-inflammatory mediators by binding to Cys747 in the intracellular domain of TLR4. This inhibits the interaction between TLR4 and its adapter molecules, Toll / IL-1 receptor domain-containing adapter protein (TIRAP) and Toll / IL-1 receptor domain-containing adapter protein (TRAM), which induces interferon-β related adapter molecules. As a result, LPS-induced signaling, including downstream signaling leading to the production of pro-inflammatory cytokines, is inhibited (Matsunaga et al. 2011). TAK-242 has an IC50 range of 1.1–11 nM. 50It has been reported to have (Ii et al. 2006). RAW 264.7 was prepared as described in Example 3, and then 1 × 10¹⁶ of it was placed in two 96-well microtiter plates. 5 Cells were seeded at a cell / well density. S. cordifolia fractions (100 μl) SCAF0 and SCAF5 (1–0.001 mg / ml) were added to one plate three times. A positive control was 1 ng / ml LPS, and a negative control was 100 μl DMEM medium. The remaining plates were arranged similarly. However, all fractions, SCAF0 and SCAF5, as well as the positive (LPS 1 ng / ml) and negative (moderate) fractions, contained TAK-242 at a concentration of 10 nM. The plates were incubated for 18 hours in a 5% CO2, 37°C incubator. After incubation, nitrite concentrations were measured using Griess reagent.

[0262] Galleria Melonella Galleria melonella larvae (Livefoods Direct) were reared on artificial feed at 25°C (darkness) and maintained in sterile petri dishes (5 cm) in a 37°C incubator during the experiment. The experimental group consisted of 10 larvae (final instar) weighing 250-300 mg.

[0263] Immune response to Galleria melonella Fractions SCAF0 and SCAF5 at concentrations of 1 mg / ml, 0.1 mg / ml, and 0.001 mg / ml were prepared in PBS under sterile conditions. Using a Terumo Myjector 1 ml 29 G 0.33 x 12 mm, 20 μl aliquots of the extract were injected into the hemocoel of each group's larvae via the prolegs (left) on the dorsolateral side, and the larvae were incubated for 24 hours. After incubation, hemolymph was removed and the blood cells were counted using a hemocytometer.

[0264] Bacterial load of larvae pre-exposed to SCAF0~SCAF5 SCAF0 and SCAF5 (0.001 mg / ml, 0.1 mg / ml, and 1 mg / ml) were prepared in PBS under sterile conditions. Using a Terumo Myjector (1 ml 29 G 0.33 x 12 mm), 10 μl aliquots of the extract were injected into the hemocoel of the larvae of each group via the prolegs (left) on the dorsolateral side, and PBS was injected into the negative control group. The larvae were placed in an incubator set to 37°C for 24 hours. 24 hours after administration of the aqueous extract, each group was infected with MRSA (ATCC 43300), and inoculation experiments were performed according to the protocol described in Ramarao et al. (2012). The density of the inoculum was standardized to the optical equivalent of the 0.5 McFarland turbidity standard, with an absorbance of 0.06-0.10 nm at λ600 nm corresponding to 107 cfu / ml (Andrews 2001). It was then diluted with PBS to prepare an inoculum with a concentration of 1 × 10⁵ CFU / ml. Infected larvae were administered via the propodus (right) on the dorsolateral side (injection volume 20 μl (2 × 10³ CFU)). The inoculated larvae were kept in an incubator at 37°C for 24 hours. The bacterial inoculum used to infect the larvae was graded, and 20 μl of each dilution was plated onto a Mueller-Hinton agar plate. The size of the inoculum was confirmed using the Misra method (Miles et al. 1938), which involves graded dilution of the bacterial inoculum, plating 20 μl of each dilution onto a Mueller-Hinton agar plate, and incubating at 37°C for 24 minutes. The concentration of the inoculum was 1.1 × 10⁵ CFU / ml. 5 CFU / ml was calculated. Three larvae were taken from each group at 24, 48, and 72 hours post-infection, and the bacterial load in the hemolymph was measured by draining and diluting the hemolymph. The CFU / ml of the hemolymph was determined by calculating CFU using the Misra method.

[0265] Effects of SC1 and SC2 administration on bacterial load in larvae Larvae (10 larvae per group, weighing 250-300 mg) were infected with MRSA (ACTCC 4330) (10 μl, 1.1 × 10⁵ CFU / ml) via the dorsolateral site through the left abdominal leg using a 1 ml Terumo Myjector syringe (29G 0.33 × 12 mm), and the larvae were then incubated for 6 hours. Compounds SC1 and SC2 were administered to the incubated larvae, and the larvae were then maintained in a 37°C incubator for 48 hours. Next, hemolymph was extracted, and the CFU / ml of the hemolymph was measured by calculating the CFU using the Misra method as described above.

[0266] GC-MS analysis SCAF0 and SCAF5 (100 mg) were hydrolyzed in a sealed 25 ml flask with 10 ml of 1 M trifluoroacetic acid (TFA) (Sigma-Aldrich) at 105°C for 7 hours (Uzaki & Ishiwatari 1983), and then lyophilized. The sample (2 mg) was derivatized by silylation with 500 μl of N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) containing 1% trimethylcrosilane (Sigma-Aldrich) in 1 ml of anhydrous pyridine. The reaction was carried out at room temperature for 12 hours. GC-MS analysis was performed using a ZB semi-volatile column (30 m x 0.25 mm x 0.25 μm Zebron). TMGas chromatography (Agilent 7890A) connected to a mass-selective detector (Agilents 5975C) equipped with Phenomenex Inc. was performed using helium as the carrier gas at a constant rate of 1 ml / min. The syringe and MS source temperatures were maintained at 260°C and 230°C, respectively. The column temperature program consisted of injection at 80°C and holding for 1 minute, heating at 15°C / min up to 300°C, and then isothermal holding at 300°C for 15 minutes. The MS operated in electron shock mode with an ionization energy of 70 eV. The scan range was set to a mass scan range of 50-550 Da. The injection volume was 1 μl, and the injection port was split into 20 ml-1 (splitting ratio 20:1). Data acquisition and processing were performed using Chemstation software (Hewlett Packard). Monomer identification was performed by comparing chromatographic retention properties, mass spectra against standard materials, and data from the NIST Mass Spectrum Library (National Institute of Standards and Technology, USA).

[0267] Real-time quantitative PCR (RT-qPCR) Preparation of RNA samples Mouse splenocyte suspension was prepared as described above. The cells were placed in a 6-well Corning® cell culture plate in a 2 × 10⁶ arrangement. 6 The cells were seeded at a density of cells / ml. Mouse macrophages (RAW 264.7) were cultured as described in Example 3. The cells were arranged in 5 × 10⁶ cells. 5Cells were seeded at a density of cells / ml. Subsequently, 1.5 ml of S. cordifolia fractions SCAF0 and SCAF5 were added to the wells of the seeding plate three times at concentrations of 1 mg / ml and 0.1 mg / ml, respectively. A positive control was 1 ng / ml of LPS, and a negative control was 1.5 DMEM or RPMI medium. The plates were incubated at 37°C for 24 hours. After incubation, cells were gently removed from the wells using a cell scraper, and the supernatant was aspirated from the plate and transferred to a sterile universal tube. Three samples of each specimen were pooled in the same universal tube. The total number of cells in each tube was measured, and after subsequent adjustment, the final cell density was 1.5 x 10⁶ for splenocytes and RAW264.7 cells, respectively. 6 cells / ml and 3x10 5 The cell count was obtained at 1 / ml. Next, the universal tube was centrifuged at 300g for 15 minutes, and the supernatant was aspirated. RNA was isolated using the Qiagen RNeasy Mini kit (Qiagen LTD, Manchester, UK). Briefly, 600 μl of RLT lysis buffer (guanidinium thiocyanate-containing lysis buffer) (Qiagen) containing 1% v / v β-mercaptoethanol was added to the universal tube containing the cell pellet, and the cells were homogenized. Next, the lysis solution was transferred to an RNAase-free Eppendorf tube, and then the tube was centrifuged at 10,000g for 3 minutes using a benchtop MiniSpin Eppendorf centrifuge (Eppendorf UK LTD, Stevenage, UK). After that, the supernatant was transferred to a 1.5 ml Eppendorf tube, and 600 μl of 70% ethanol was added to it. Subsequently, 700 μl of the sample was transferred to a spin column in a 2 ml collection tube, centrifuged at 10,000 g for 1 minute, and then the remaining sample was passed through the spin column.

[0268] Next, the spin column was transferred to a clean collection column and the filtrate was discarded. Then, 700 μl of RW1 buffer was centrifuged at 10000 g for 1 minute, followed by 500 μl of RPE buffer being centrifuged on the column at 10000 g, followed by another 500 μl of RPE buffer being centrifuged at 10000 g for 2 minutes, and then further centrifuged at 11000 g for 1 minute to pass through the spin column. RNA was eluted from the column membrane by adding 50 μl of RNase-free water and centrifuging at 10000 g.

[0269] The sample is TURBO TM Genomic DNA was removed from RNA samples by simple treatment with DNase (Life Technologies). 10X TURBO DNase buffer (containing divalent cations Ca2+ and Mg2+ essential for maximal DNase enzyme activity) was added at a 1X concentration, followed by 1 μl of TURBO DNase (2U), and the tubes were incubated at 37°C for 30 minutes. The purity of the isolated RNA was assessed using the ratio of absorbance at 260 nm and 280 nm, quantified using a NanoDrop 2000c spectrophotometer (Thermo Scientific, Loughborough, UK), and the sample ratio was calculated as 2.0–2.1 for all samples. RNA samples were stored at -80°C before cDNA synthesis.

[0270] Reverse transcription, cDNA synthesis RNA concentration was quantified by absorbance at 260 nm using NanoDrop 2000c. The range was determined to be 167.1 ng / μl to 0.88 ng / μl. The RNA concentration was adjusted to 150 ng / μl using RNase-free water before cDNA synthesis. Reverse transcription was performed using a Transcriptor First-Strand cDNA synthesis kit (Roche Diagnostics Ltd, Sussex, UK) with random hexamer primers, and the reverse transcription was performed three times according to the manufacturer's protocol. The RNA concentration used in all reactions was 1 μg. The transcription reaction was performed on an Eppendorf Mastercycler. The reaction setting involved inactivating the reverse transcriptase by heating at 25°C for 10 minutes, 55°C for 30 minutes, and finally at 85°C for 5 minutes.

[0271] RT-qPCR RT-qPCR was performed according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines (Bustin et al. 2009). To determine a reference gene for normalization, the stability of gene expression must be altered under experimental conditions (Kozera & Marcin 2013). Therefore, the stability of β-actin, β-2-microglobulin (B2M), glyceraldehyde 3-phosphate (GADPH), hydroxymethylvilan synthase (HMBS), and hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1) was tested. HPRT1 was identified as the most stable gene, and its expression remained unchanged; therefore, it was used as the reference gene for assay normalization. A rimer sequence with published efficiencies of 90–110% in the 2-step Sybr Green assay was identified and used for primer design. After amplification, the melting curve was examined for primer dimer artifacts to ensure reaction specificity. Electrophoresis of the RT-PCR product on a 1.0% agarose gel revealed the presence of the predicted-size amplicon and the absence of nonspecific amplification products.

[0272] [Table 4]

[0273] The PCR reaction was performed using a 23 μl reaction mixture containing 100 ng of cDNA template, 0.25 μM each of forward and reverse primers (see Table 4), 12.5 μl of QuantiTect SYBR Green master mix (Qiagen LTD, Manchester, UK), and 9.25 μl of H2O (RNase-free). The reaction was performed thermally on a LightCycle® 480 system (Roche Diagnostics Ltd, Sussex, UK) under the following conditions: denaturation at 94°C for 15 seconds, annealing at 58°C for 1 minute, and extension at 72°C for 45 cycles. Electrophoresis of the RT-PCR product on a 1.0% agarose gel revealed the presence of amplicons of the predicted size.

[0274] The results were quantified using the comparative Ct method (Pfaffl 2001), which involves normalizing the target gene to a reference gene (HPRT1) and then comparing the Ct value of the treated sample (TRT) with that of a sample (CTL) (untreated cells) that functions as a calibrator.

number

[0275] result Lymphocyte assay Lymphocyte proliferation assay The results of proliferation assays using lymphocytes are summarized in Figure 36. A concentration-dependent increase in stimulatory activity was evident in both SCAF3 and SCAF5.

[0276] antibody secretion The supernatant was collected from wells containing splenocytes and incubated with a fraction of Sida cordifolia aqueous extract, and antibody secretion was measured. The results of the IgG, IgM, and IgA antibody secretion assays are shown in Figures 37, 38, and 39, respectively. Concentration-dependent increases in stimulatory activity were observed in SCAF3 and SCAF5.

[0277] Macrophage assay (RAW 264.7). Phagocytic assay. The results of the neutral red phagocytosis assay are shown in Figure 40. A concentration-dependent increase in activity was observed in SCAF5.

[0278] Production of nitric oxide (NO) Nitric oxide (NO) production was photometrically detected, measured, and quantified using colorimetric analysis (Griess reaction) as an accumulation of nitrite, a stable product in the culture supernatant. Elevated NO levels are a clear indicator of RAW264 macrophage cell activation. A concentration-dependent increase in activity was observed in SCAF5 cells (Figures 41, 51, and 52). The median effect concentration of polysaccharide to stimulate nitric oxide production in RAW264.7 cells is approximately 8 μg / ml. In these cells, the polysaccharide reaches a maximum response at approximately 25 μg / ml.

[0279] Cytokine production The polysaccharides induced macrophages and microglia to release cytokines related to the immune response. Macrophages produced IL-6 and TNFα in a concentration-dependent manner in response to contact with the polysaccharides according to the present invention (see Figure 53).

[0280] Polysaccharides also induced or suppressed the production of cytokines related to the immune response in human umbilical vein endothelial cells (HUVECs). HUVECs released IL-8 in response to contact with polysaccharides and suppressed MIG release in response to contact with the polysaccharides according to the present invention (see Figure 54).

[0281] Consideration This example demonstrates that a purified extract from S. cordifolia possesses immunomodulatory activity. This dual activity makes S. cordifolia highly unique and extremely useful for treating and / or preventing infection. In this study, the source of the immunomodulatory activity was isolated and investigated. It was identified that the immunomodulatory activity originates from polysaccharide components.

[0282] immunomodulation Initial screening in Example 3 identified that the immunomodulatory activity originated from the aqueous extract. Further fractionation revealed that this activity was derived from polysaccharides in the aqueous extract (SCAF0). Comparing the activity of SCAF0 to that of the crude aqueous extract, SCAF0 showed higher activity. In this example, SCAF0 was further fractionated by ion-exchange chromatography. The fractions obtained by ion-exchange chromatography were further fractionated according to molecular size. The fraction designated SCAF5 was found to possess the greatest immunomodulatory activity. This stimulating activity of SCAF5 was observed to be stronger than that of concanavalin A, a positive control lectin at 100 μg / ml. This observation is fully supported by studies showing elevated IgG, IgM, and IgA levels, as well as stimulated macrophage activation and phagocytosis. SCAF5 has high ionic strength and a molecular size of over 100 kDa. Electrophoretic studies performed showed that the polysaccharide size ranged from 100 kDa to 150 kDa. SCAF2 and SCAF4, with molecular weights in the 10–100 kDa range, exhibited more moderate activity profiles, suggesting that polysaccharide size is a key determinant of immunomodulatory activity. SCAF4 elicited a response in the neutral red phagocytosis assay, but neither SCAF2 nor SCAF4 significantly affected nitrite production in macrophages, thus consistent with the weaker activity of these fractions. The potent activity of SCAF5 was tested in vivo in a Galleria model. SCAF5 resulted in a significant increase in hematopoietic cells in the hemolymph.

[0283] Furthermore, administering SCAF5 to the Galleria model prevented the development of MRSA infection in the larvae. This effect was dose-dependent.

[0284] SCAF5 stimulation-induced NO production in macrophages was confirmed by RT-qPCR analysis, resulting in a 2.1-fold increase in iNOS expression. The increase in iNOS expression and NO production was observed in T H1. This shows an intervening response (Lawrence & Hagemann 2012, Stuehr & Marletta 1985). H 1. Intermediate responses contribute to bactericidal activity (i.e., respiratory bursts due to the production of reactive oxygen species). H The activation of response 1 was further supported by the observation of increased phagocytic activity in macrophages. H 1. More conclusive evidence for an intervening response was increased cytokine expression in both RAW264.7 cells and mouse splenocytes. Expression of IL-6, a pro-inflammatory itokine normally secreted by T cells and activated macrophages, was increased 4.2-fold and 3.3-fold, respectively, by SCAF5 in splenocytes and macrophages.

[0285] T H 1. IL-6, a characteristic of the intermediated immune response, is secreted by macrophages in response to PAMP. The importance of IL-6 in infection has been previously demonstrated using an in vivo model in which C57B1 / 6 mice lacking the IL-6 gene showed reduced defense against pneumococcal pneumonia (streptococcal pneumonia) (Poll et al. 1997). SCAF5 is T H Further evidence strongly suggests that it triggers an immune-mediated response. H T of 0 (naive T cell) HIncreased expression of IL-12, which is involved in differentiation into single cells, resulted in the production of IFN-γ and IFN-γ from activated T cells and NK cells (Jacobson et al. 1995). SCAF5 increased TNF-α 1.2-fold and 2-fold in splenocytes and RAW264.7 cells, respectively. TNF-α is produced by many types of cells, including monocytes, macrophages, T lymphocytes, B lymphocytes, and NK cells. TNF-α, a characteristic of activated macrophages, is involved in wound healing and tissue remodeling, exhibiting angiogenesis (Leibovich et al. 1987) while simultaneously promoting fibroblast proliferation (Battegay et al. 1995). TNF-α, along with IL-1 and IL-6, is thought to be involved in promoting the release of proteins from the liver, including C-reactive proteins that bind to phosphocholine expressed on microorganisms. This binding activates complement (Black et al. 2004), ultimately leading to the removal of pathogens. In splenocytes responding to SCAF5, 2.5-fold and 2.4-fold increases in IFN-γ and IFN-β were observed, respectively. Since IFN-γ is characteristic of activated T lymphocytes and natural killer cells, this indicates the presence of activated T cells and NK cells within the splenocyte population. IFN-γ possesses antiproliferative and antiviral properties and is a potent activator of mononuclear phagocytes, thus enhancing the ability to destroy intracellular microorganisms (Huang et al. 1993). Mice lacking IFN-γ were sacrificed by sublethal doses of pathogens, including Mycobacterium bovine tuberculosis, an intracellular pathogen shown to be lethal even at sublethal doses in mice (Dalton et al. 1993). Similar to IFN-γ, IFN-β also exhibits antiviral activity (Damme et al. 1987). 2.5-fold and 2.4-fold increases in IL-1β expression were also observed in SCAF5 in both RAW 264.7 cells and splenocytes. IL-1, secreted from phagocytic cells, acts as a lymphocyte activator and mitogen for lymphocytes, and is also involved in nonspecific resistance to pathogens.IL-1 has been shown to be suppressed by corticosteroids, as well as IL-12, IL-6, IFN-γ, IFN-β, and TNF-α (Miyaura & Iwata 2002, Lew et al. 1988). The ability of SCAF5 to increase these pro-inflammatory cytokines is T. H 1. This may be a valid reason to use it as a stimulant for the 1-mediated response. Since there was no change in IL-10 expression in both RAW264.7 and splenocyte cultures, H Further evidence supporting the proposed intermediated immune response was obtained. The absence of endotoxin (LPS) in SCAF0-5 was confirmed by LAL assay. Furthermore, the inability of TAK-242 to inhibit macrophage activation was confirmed by the inactivation of cells incubated in the presence of TAK-242 and LPS. This suggests that the pattern recognition receptor (PRR) responsible for macrophage activation is not TLR-4, and that this activity is not due to the presence of endotoxin contaminants. GC-MS analysis of the polysaccharides in SCAF0 and SCAF5 revealed similar monomer components but different sugar ratios. SCAF5 had high levels of both uronic acid and glucuronic acid, which may explain the need for a high ionic strength solution to elute SCAF5. The increased proportion of mannose in SCAF5 may suggest that the mannose receptor is a mediator of immunomodulatory activity.

[0286] conclusion This example demonstrates that polysaccharides (PP) from *Sida cordifolia* exhibit immunomodulatory activity. The immunomodulatory activity is induced by polysaccharide molecules isolated with a molecular weight of >100 kDa. No endotoxins were detected, as confirmed by the LAL assay. Since TAK 242 could not inhibit the immune response, the immunomodulatory activity is not considered to be a result of direct activation of the TLR4 receptor. SCAF5 has a higher proportion of mannose monosaccharides compared to the less active fractions (SCAF1-4), suggesting that immune activation may be induced by mannose receptor activation. The cytokine profile induced by SCAF5 indicates that the immune system is most critical to microbial attack. H This strongly suggests a single-cell-mediated pro-inflammatory immune response. The increase in iNOS in macrophages also suggests a pro-inflammatory immune response.

[0287] Example 5 - Effects of polysaccharides on fecal bacteria diversity Fecal samples from C57Bl / 6J mice were evaluated to determine their bacterial composition. Mice were orally administered daily with either saline (0.9%) or saline containing purified polysaccharide (300 mg / kg). The polysaccharide was prepared according to the "Strategy 3" methodology described herein (shown in Figure 1). Figure 55 shows the % composition (at the phylum level) of the fecal microbiota in mice after 7 days of treatment with polysaccharide or saline. Figure 56 is a summary of the bacterial diversity (from Figure 55) when analyzed at the phylum and species levels (alpha diversity was calculated using the Shannon index). Figures 55 and 56 clearly demonstrate that the polysaccharide according to the present invention increases fecal bacterial diversity at the phylum and species levels in C57Bl / 6J mice. Therefore, the polysaccharide according to the present invention can be used as a prebiotic.

Claims

1. A polysaccharide comprising "n" repeating units, each of which comprises alpha-(1-5)-linked arabinofuranose residues as a backbone, a first side chain which is a single alpha-arabinofuranose residue (1-2) attached to the arabinofuranose residue of the backbone, and a second side chain which is a single alpha-arabinofuranose residue (1-3) attached to the same arabinofuranose residue of the backbone.

2. The repeating unit has the formula (I): 【Chemistry 1】 (This is sometimes referred to as Block "A") 2. The polysaccharide of claim 1, comprising or consisting of:

3. The repeating unit has the formula (II): 【Chemistry 2】 3. The polysaccharide of claim 1, further comprising a block E represented by:

4. The repeating unit has the formula (III): 【Chemistry 3】 4. The polysaccharide according to claim 1, further comprising a block F of the formula:

5. 5. The polysaccharide according to claim 2, wherein the backbone of each block is linked by alpha-(1-5)-glycosidic bonds.

6. 6. The polysaccharide of claim 2, wherein the ratio of A:E:F in the repeating units is 4-6:1-2:

1.

7. 6. The polysaccharide according to any one of claims 2 to 5, wherein the ratio of A:F in the repeating unit is 4 to 6:

1.

8. 6. The polysaccharide of claim 2, wherein the ratio of A:E in the repeating unit is from 2 to 6:

1.

9. The repeating unit has the formula (IV): 【Chemistry 4】 [Each asterisk in formula (IV) corresponds to an arabinofuranose, preferably an L-arabinofuranose, more preferably an alpha-arabinofuranose, most preferably an alpha-L-arabinofuranose] 2. The polysaccharide of claim 1, comprising:

10. 10. The polysaccharide according to any one of claims 1 to 9, wherein "n" is from 5 to 1000, from 10 to 500, or from 15 to 250, or from 15 to 230, or from 15 to 220, preferably "n" is from 15 to 220 or from 15 to 230.

11. A method for isolating the polysaccharide of the present invention from a Malvales plant, comprising the steps of: i. homogenizing and dehydrating the Malvales plant to form dehydrated Malvales plant particles and / or powder; and ii. isolating polysaccharides from the Malvales plant by extracting the polysaccharides from the dehydrated Malvales plant particles and / or powder; The method includes:

12. 12. The method of claim 11, wherein homogenizing the Malvales plant comprises grinding and / or shredding the plant into particles and / or powder.

13. 13. The method of claim 11 or 12, wherein dehydrating the Malvales plant comprises freeze-drying or heating the plant material to remove water.

14. 14. The method according to any one of claims 11 to 13, wherein extracting polysaccharides from dehydrated Malvales plant particles or powder comprises a first alcoholic extraction step, followed by one or more aqueous extraction steps, followed by a second alcoholic extraction step.

15. 15. The method of claim 14, wherein the second alcoholic extraction step is carried out with the aqueous phase of one or more aqueous extraction steps that are pooled to form an alcoholic phase containing the isolated polysaccharides and precipitate.

16. 16. The method of claim 15, wherein the alcohol phase is separated from the precipitate by centrifugation.

17. 17. The method of claim 16, further comprising a purification step, such as a chromatographic, crystallization or distillation technique.

18. 18. An isolated polysaccharide produced by the method of any one of claims 11 to 17.

19. A culture medium comprising an isolated polysaccharide according to any one of claims 1 to 10, or an isolated polysaccharide produced by the method according to any one of claims 11 to 17.

20. 20. The culture medium of claim 19, which is a cloning medium or a hybridoma feeder supplement.

21. 21. The culture medium of claim 19 or 20, further comprising a cell, a biological tissue, a biological organ or an organism.

22. A composition comprising a polysaccharide according to any one of claims 1 to 10, or an isolated polysaccharide produced by the method according to any one of claims 11 to 17, optionally wherein the composition is a pharmaceutical composition and is coupled with a pharma- ceutically acceptable carrier or the like, or is an edible composition (e.g. a prebiotic).

23. An immunological adjuvant comprising an isolated polysaccharide according to any one of claims 1 to 10 or produced by the method according to any one of claims 11 to 17.

24. 24. A vaccine comprising the immunological adjuvant of claim 23.

25. A pharmaceutical comprising a polysaccharide according to any one of claims 1 to 10, an isolated polysaccharide produced by a method according to any one of claims 11 to 17, a composition according to claim 22, an immunological adjuvant according to claim 23 or a vaccine according to claim 24.

26. A pharmaceutical for treating, ameliorating or preventing a disease or condition in a subject, comprising a polysaccharide described in any one of claims 1 to 10, an isolated polysaccharide produced by a method described in any one of claims 11 to 17, a composition described in claim 22, an immunological adjuvant described in claim 23, or a vaccine described in claim 24.

27. A pharmaceutical for treating, ameliorating or preventing a helper T cell (TH)-mediated disease or condition in a subject, comprising a polysaccharide according to any one of claims 1 to 10, an isolated polysaccharide produced by the method according to any one of claims 11 to 17, a composition according to claim 22, an immunological adjuvant according to claim 23, a vaccine according to claim 24, or a plant of the order Malvales or a part thereof.

28. Helper T cells (T H ) The intervening disease or condition is T H 1 Intervening disease or condition, or T H 28. The method of claim 27, which is a bi-mediated disease or condition.

29. T H 1 The intervening disease or condition is rheumatoid arthritis (RA); psoriatic arthritis; psoriasis; Inflammatory Bowel Syndrome (IBD); Crohn's Disease; Ulcerative colitis; multiple sclerosis (MS); influenza (including pandemic influenza); respiratory disorders, e.g. those caused by viruses such as respiratory syncytial virus (RSV); cystic fibrosis (CF); herpes (including genital herpes); sepsis and septic shock; bacterial pneumonia; bacterial meningitis; dengue hemorrhagic fever; endometriosis; prostatitis; uveitis; uterine ripening; alopecia areata; ankylosing spondylitis; celiac disease; dermatomyositis; type 1 diabetes; Goodpasture's syndrome; Graves' disease; Guillain-Barré syndrome; juvenile idiopathic arthritis; Hashimoto's thyroiditis; idiopathic thrombocytopenic purpura; lupus erythematosus and / or one or more selected from the group consisting of: chronic myocardial infarction, chronic obstructive pulmonary disease, chronic pulmonary disease, chronic pulmonary edema ... H 29. The pharmaceutical of claim 28, wherein the one-mediated disease or condition is cystic fibrosis (CF), type I diabetes, age-related macular degeneration, an infectious disease (e.g., Mycobacterium tuberculosis (Mt) infection, human immunodeficiency virus (HIV) infection or coronavirus infection).

30. T H 29. The pharmaceutical composition of claim 28, wherein the 2-mediated disease or condition is preferably one or more selected from the group including / consisting of type 1 hypersensitivity disorders (including allergies (e.g. rhinitis, allergic dermatitis, urticaria), asthma, eczema, hay fever, urticaria, chronic graft-versus-host disease, progressive systemic sclerosis, systemic lupus erythematosus); chronic lung disease; scleroderma; anaphylaxis; atrophy (e.g. muscle); and graft rejection.

31. A pharmaceutical composition according to any one of claims 25 to 30, which is administered orally, sublingually, topically, transdermally or parenterally (subcutaneously, intramuscularly or intravenously).

32. A method for culturing a cell, a biological tissue, a biological organ or a biological system comprising: placing a cell, biological tissue, biological organ or biological system in the culture medium; and Placing in a culture medium (i) a polysaccharide according to claims 1 to 10, (ii) an isolated polysaccharide produced by a method according to any one of claims 11 to 17, (iii) a composition according to claim 22, (iv) an adjuvant according to claim 23, (v) a vaccine according to claim 24, or (vi) a plant of the order Malvales or a part thereof. The method includes:

33. T H 1. An in vitro method for inducing or enhancing an IgM-mediated immune response, comprising: T H contacting an organism, biological system, biological tissue, biological organ or cell with a polysaccharide according to any one of claims 1 to 10 so as to induce or enhance a .alpha.-mediated immune response; or T H administering a polysaccharide according to any one of claims 1 to 10 to an organism, a biological system, a biological tissue, a biological organ or a cell so as to induce or enhance a 1-mediated immune response; The method includes:

34. T H 1. An in vitro method for preventing or attenuating a .2-mediated immune response, comprising: T H Administering a polysaccharide according to any one of claims 1 to 10 to an organism, biological system, biological tissue, biological organ or cell to prevent or attenuate a .DELTA. ... T H 11. A method for preventing or attenuating a .DELTA. ...